

September 1999

M21-A
Vol. 19 No. 17
Replaces M21-T
Vol. 12 No. 19

Methodology for the Serum Bactericidal Test; Approved Guideline

This document provides a direct method of antimicrobial susceptibility testing using serum obtained from the patient to measure the activity of the serum against the bacterial pathogen isolated from the patient.



NCCLS...

Serving the World's Medical Science Community Through Voluntary Consensus

NCCLS is an international, interdisciplinary, nonprofit, standards-developing, and educational organization that promotes the development and use of voluntary consensus standards and guidelines within the healthcare community. It is recognized worldwide for the application of its unique consensus process in the development of standards and guidelines for patient testing and related healthcare issues. NCCLS is based on the principle that consensus is an effective and cost-effective way to improve patient testing and healthcare services.

In addition to developing and promoting the use of voluntary consensus standards and guidelines, NCCLS provides an open and unbiased forum to address critical issues affecting the quality of patient testing and health care.

PUBLICATIONS

An NCCLS document is published as a standard, guideline, or committee report.

Standard A document developed through the consensus process that clearly identifies specific, essential requirements for materials, methods, or practices for use in an unmodified form. A standard may, in addition, contain discretionary elements, which are clearly identified.

Guideline A document developed through the consensus process describing criteria for a general operating practice, procedure, or material for voluntary use. A guideline may be used as written or modified by the user to fit specific needs.

Report A document that has not been subjected to consensus review and is released by the Board of Directors.

CONSENSUS PROCESS

The NCCLS voluntary consensus process is a protocol establishing formal criteria for:

- the authorization of a project
- the development and open review of documents
- the revision of documents in response to comments by users
- the acceptance of a document as a consensus standard or guideline.

Most NCCLS documents are subject to two levels of consensus- "proposed" and "approved." Depending on

the need for field evaluation or data collection, documents may also be made available for review at an intermediate (i.e., "tentative") consensus level.

Proposed An NCCLS consensus document undergoes the first stage of review by the healthcare community as a proposed standard or guideline. The document should receive a wide and thorough technical review, including an overall review of its scope, approach, and utility, and a line-by-line review of its technical and editorial content.

Tentative A tentative standard or guideline is made available for review and comment only when a recommended method has a well-defined need for a field evaluation or when a recommended protocol requires that specific data be collected. It should be reviewed to ensure its utility.

Approved An approved standard or guideline has achieved consensus within the healthcare community. It should be reviewed to assess the utility of the final document, to ensure attainment of consensus (i.e., that comments on earlier versions have been satisfactorily addressed), and to identify the need for additional consensus documents.

NCCLS standards and guidelines represent a consensus opinion on good practices and reflect the substantial agreement by materially affected, competent, and interested parties obtained by following NCCLS's established consensus procedures. Provisions in NCCLS standards and guidelines may be more or less stringent than applicable regulations. Consequently, conformance to this voluntary consensus document does not relieve the user of responsibility for compliance with applicable regulations.

COMMENTS

The comments of users are essential to the consensus process. Anyone may submit a comment, and all comments are addressed, according to the consensus process, by the NCCLS committee that wrote the document. All comments, including those that result in a change to the document when published at the next consensus level and those that do not result in a change, are responded to by the committee in an appendix to the document. Readers are strongly encouraged to comment in any form and at any time on any NCCLS document. Address comments to the NCCLS Executive Offices, 940 West Valley Road, Suite 1400, Wayne, PA 19087, USA.

VOLUNTEER PARTICIPATION

Healthcare professionals in all specialties are urged to volunteer for participation in NCCLS projects. Please contact the NCCLS Executive Offices for additional information on committee participation.

Methodology for the Serum Bactericidal Test; Approved Guideline

Abstract

Bactericidal testing methods occasionally are used because of the awareness of the need for lethal antimicrobial activity to treat certain deep-seated infections, e.g., bacterial endocarditis. There also is an increased awareness of the need to consider the pharmacodynamic and pharmacokinetic principles of antimicrobial therapy. This often can be achieved by assessing both results of standardized susceptibility testing and of antimicrobial assays. The serum bactericidal test represents an alternative *in vitro* test that incorporates pharmacodynamic and pharmacokinetic principles. The test takes into consideration the susceptibility of the pathogen; measures the combined effect of absorption and elimination of the antibiotic; the binding of the drug to serum proteins; and the effect of the parent compound as well as any metabolites against the infecting organism. This assay also measures the effect of drug interactions. This includes both the synergistic or antagonistic effects of antibiotic combinations and the interactions of other drugs with antibiotics. Finally, the serum bactericidal test, by measuring the magnitude of antibiotic concentration relative to the MBC, allows a prediction of the aggregate time of bactericidal activity. Peak serum bactericidal titers of > 8 , for example, assure measurable bactericidal activity in the serum for at least three half-lives of the drug being tested. Despite all of these potential advantages, the serum bactericidal test rarely is needed. Although the test provides another predictive estimate of bacterial eradication, clinical cure depends largely upon host factors and other factors, e.g., postantibiotic effect and the growth-inhibitory effects of sub-MIC concentrations of antibiotics. When needed, however, established, reproducible methods should be available to the clinical, reference, and/or research laboratory.

(NCCLS. *Methodology for the Serum Bactericidal Test; Approved Guideline*. NCCLS document M21-A [ISBN 1-56238-383-3]. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087 USA, 1999.)

THE NCCLS consensus process, which is the mechanism for moving a document through two or more levels of review by the healthcare community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of NCCLS documents. Current editions are listed in the *NCCLS Catalog*, which is distributed to member organizations, and to nonmembers on request. If your organization is not a member and would like to become one, and to request a copy of the *NCCLS Catalog*, contact the NCCLS Executive Offices. Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: exoffice@nccls.org

M21-A

ISBN 1-56238-383-3

ISSN 0273-3099

September 1999

Methodology for the Serum Bactericidal Test; Approved Guideline

Volume 19 Number 17

Arthur L. Barry, Ph.D.

William A. Craig, M.D.

Harriette Nadler, Ph.D.

L. Barth Reller, M.D.

Christine C. Sanders, Ph.D.

Jana M. Swenson, M.M.Sc.



This publication is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without written permission from NCCLS, except as stated below.

NCCLS hereby grants permission to reproduce limited portions of this publication for use in laboratory procedure manuals at a single site, for interlibrary loan, or for use in educational programs provided that multiple copies of such reproduction shall include the following notice, be distributed without charge, and, in no event, contain more than 20% of the document's text.

Reproduced with permission, from NCCLS publication M21-A— *Methodology for the Serum Bactericidal Test; Approved Guideline*. Copies of the current edition may be obtained from NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087 USA.

Permission to reproduce or otherwise use the text of this document to an extent that exceeds the exemptions granted here or under the Copyright Law must be obtained from NCCLS by written request. To request such permission, address inquiries to the Executive Director, NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087 USA.

Copyright ©1999. The National Committee for Clinical Laboratory Standards.

Suggested Citation

(NCCLS. *Methodology for the Serum Bactericidal Test; Approved Guideline*. NCCLS document M21-A [ISBN 1-56238-383-3]. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087 USA, 1999.)

Proposed Guideline

January 1987

Tentative Guideline

September 1992

Approved Guideline

September 1999

ISBN 1-56238-383-3
ISSN 0273-3099

Committee Membership**Area Committee on Microbiology**

James H. Jorgensen, Ph.D.
Chairholder

University of Texas Health Science Branch
San Antonio, Texas

Melvin P. Weinstein, M.D.
Vice-Chairholder

Robert Wood Johnson Medical School
New Brunswick, New Jersey

Arthur L. Barry, Ph.D.

Clinical Microbiology Institute
Wilsonville, Oregon

Sharon L. Hansen, Ph.D.

Food and Drug Administration
Rockville, Maryland

Stephen G. Jenkins, Ph.D.

Mt. Sinai Medical Center
New York, New York

J. Michael Miller, Ph.D.

Centers for Disease Control and Prevention
Atlanta, Georgia

Jeffrey L. Watts, M.S., R.M.(AAM)

Pharmacia & Upjohn Animal Health
Kalamazoo, Michigan

Advisors

Ellen Jo Baron, Ph.D.

Stanford Hospital & Clinics
Stanford, California

Stanley Bauer, M.D.

Beth Israel Medical Center
New York, New York

Gary V. Doern, Ph.D.

University of Iowa
Iowa City, Iowa

George L. Evans, Ph.D.

White Haven, Pennsylvania

Mary Jane Ferraro, Ph.D.

Massachusetts General Hospital
Boston, Massachusetts

John N. Galgiani, M.D.

VA Medical Center
Tuscon, Arizona

Lynne S. Garcia, M.S.

UCLA Medical Center
Los Angeles, California

Richard L. Hodinka, Ph.D.

Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Michael A. Pfaller, M.D.

University of Iowa College of Medicine
Iowa City, Iowa

Robert P. Rennie, Ph.D.

University of Alberta Hospital
Edmonton, Alberta

Thomas R. King, M(ASCP)
Staff Liaison

NCCLS
Wayne, Pennsylvania

Patrice E. Polgar
Editor

NCCLS
Wayne, Pennsylvania

Donna M. Wilhelm
Assistant Editor

NCCLS
Wayne, Pennsylvania

Acknowledgments

Special recognition is given to the following persons whose help with the development of this document was extremely valuable:

William A. Craig, M.D.

William S. Middleton VA Hospital
Madison, Wisconsin

Harriette Nadler, Ph.D.

Rhône-Poulenc Rorer
Collegeville, Pennsylvania

L. Barth Reller, M.D.

Duke University Medical Center
Durham, North Carolina

Christine C. Sanders, Ph.D.

Creighton University School of Medicine
Omaha, Nebraska

Jana M. Swenson, M.M.Sc.

Centers for Disease Control and Prevention
Atlanta, Georgia

ACTIVE MEMBERSHIP (as of 1 July 1999)**Sustaining Members**

Abbott Laboratories
 American Association for
 Clinical Chemistry
 Bayer Corporation
 Beckman Coulter, Inc.
 Becton Dickinson and Company
 bioMérieux, Inc.
 College of American
 Pathologists
 Dade Behring Inc.
 Nippon Becton Dickinson Co,
 Ltd.
 Ortho-Clinical Diagnostics, Inc.
 Pfizer Inc
 Roche Diagnostics, Inc.

Professional Members

American Academy of Family
 Physicians
 American Association of
 Bioanalysts
 American Association of Blood
 Banks
 American Association for
 Clinical Chemistry
 American Association for
 Respiratory Care
 American Chemical Society
 American Medical Technologists
 American Public Health
 Association
 American Society for Clinical
 Laboratory Science
 American Society of
 Hematology
 American Society for
 Microbiology
 American Society of
 Parasitologists, Inc.
 American Type Culture
 Collection, Inc.
 Asociación Española Primera de
 Socorros (Uruguay)
 Asociacion Mexicana de
 Bioquímica Clínica A.C.
 Assn. of Public Health
 Laboratories
 Assoc. Micro. Clinici Italiani-
 A.M.C.L.I.
 Australasian Association of
 Clinical Biochemists
 British Society for Antimicrobial
 Chemotherapy
 Canadian Society for Medical
 Laboratory Science—Société
 Canadienne de Science de
 Laboratoire Médical

Canadian Society of Clinical
 Chemists
 Clinical Laboratory Management
 Association
 College of American
 Pathologists
 College of Medical Laboratory
 Technologists of Ontario
 College of Physicians and
 Surgeons of Saskatchewan
 Commission on Office
 Laboratory Accreditation
 Danish Society of Clinical
 Chemistry
 Fundacion Bioquímica de la
 Provincia (Argentina)
 International Association of
 Medical Laboratory
 Technologists
 International Council for
 Standardization in
 Haematology
 International Federation of
 Clinical Chemistry
 International Society for
 Analytical Cytology
 Italian Society of Clinical
 Biochemistry
 Japan Society of Clinical
 Chemistry
 Japanese Committee for Clinical
 Laboratory Standards
 Joint Commission on
 Accreditation of Healthcare
 Organizations
 National Academy of Clinical
 Biochemistry
 National Society for
 Histotechnology, Inc.
 Ontario Medical Association
 Laboratory Proficiency Testing
 Program
 Ordre professionnel des
 technologues médicaux du
 Québec
 RCPA Quality Assurance
 Programs PTY Limited
 Sociedade Brasileira de Analises
 Clinicas
 Sociedade Brasileira de
 Patologia Clínica
 Sociedad Espanola de Quimica
 Clínica
 VKCN (The Netherlands)

Government Members

Armed Forces Institute of
 Pathology
 Association of Public Health
 Laboratory Directors
 BC Centre for Disease Control
 Centers for Disease Control and
 Prevention
 Chinese Committee for Clinical
 Laboratory Standards
 Commonwealth of Pennsylvania
 Bureau of Laboratories
 Department of Veterans Affairs
 Deutsches Institut für Normung
 (DIN)
 FDA Center for Devices and
 Radiological Health
 FDA Division of Anti-Infective
 Drug Products
 Health Care Financing
 Administration
 Iowa State Hygienic Laboratory
 Massachusetts Department of
 Public Health Laboratories
 Michigan Department of Public
 Health
 National Association of Testing
 Authorities - Australia
 National Center of Infectious
 and Parasitic Diseases
 (Bulgaria)
 National Institute of Standards
 and Technology
 Ohio Department of Health
 Oklahoma State Department of
 Health
 Ontario Ministry of Health
 Saskatchewan Health-
 Provincial Laboratory
 South African Institute for
 Medical Research
 Swedish Institute for Infectious
 Disease Control

Industry Members

AB Biodisk
 Abbott Laboratories
 AccuMed International, Inc.
 Accumetrics, Inc.
 Amersham Pharmacia Biotech
 Ammirati Regulatory Consulting
 Assessor
 AstraZeneca
 Avocet Medical, Inc.
 Bayer Corporation - Elkhart, IN
 Bayer Corporation - Middletown,
 VA

Bayer Corporation - Tarrytown, NY
 Bayer Corporation - West Haven, CT
 Bayer Medical Ltd.
 Beckman Coulter, Inc.
 Beckman Coulter, Inc. Primary Care Diagnostics
 Beckman Coulter K.K. (Japan)
 Becton Dickinson and Company
 Becton Dickinson Biosciences
 Becton Dickinson Consumer Products
 Becton Dickinson Immunocytometry Systems
 Becton Dickinson Italia S.P.A.
 Becton Dickinson VACUTAINER Systems
 bioMérieux, Inc.
 Biometrology Consultants
 Bio-Rad Laboratories, Inc.
 Biotest AG
 Bristol-Myers Squibb Company
 Canadian Reference Laboratory Ltd.
 CASCO•NERL Diagnostics
 Checkpoint Development Inc.
 Chiron Diagnostics Corporation - International Operations
 Chiron Diagnostics Corporation - Reagent Systems
 Clinical Lab Engineering
 COBE Laboratories, Inc.
 Combact Diagnostic Systems Ltd.
 Community Medical Center (NJ)
 Control Lab (Brazil)
 Cosmetic Ingredient Review
 Cubist Pharmaceuticals
 Cytometrics, Inc.
 Dade Behring Inc. - Deerfield, IL
 Dade Behring Inc. - Glasgow, DE
 Dade Behring Inc. - Marburg, Germany
 Dade Behring Inc. - Miami, FL
 Dade Behring Inc. - Sacramento, CA
 Dade Behring Inc. - San Jose, CA
 DAKO A/S
 Diagnostic Products Corporation
 DiaSorin
 Eiken Chemical Company, Ltd.
 Enterprise Analysis Corporation
 Fort Dodge Animal Health
 Gen-Probe
 Glaxo-Wellcome, Inc.
 Greiner Mediatech, Inc.
 Health Systems Concepts, Inc.
 Helena Laboratories
 Hycor Biomedical Inc.
 I-STAT Corporation

Instrumentation Laboratory
 Integ, Inc.
 International Technidyne Corporation
 Johnson City Medical Center
 Kendall Sherwood-Davis & Geck
 Labtest Diagnostica S.A.
 LifeScan, Inc. (a Johnson & Johnson Company)
 LifeSign, LLC
 Lilly Research Laboratories
 Medical Device Consultants, Inc.
 Medical Laboratory Automation Inc.
 MediSense Products (Div. Of Abbott Laboratories)
 Medtronic Perfusion Systems
 Merck & Company, Inc.
 Nabi
 Neometrics Inc.
 Nichols Institute Diagnostics (Div. of Quest Diagnostics, Inc.)
 Nissui Pharmaceutical Co., Ltd.
 Nippon Becton Dickinson Co., Ltd.
 Norfolk Associates, Inc.
 OBC Associates
 Olympus Corporation
 Optical Sensors, Inc.
 Organon Teknika Corporation
 Ortho-Clinical Diagnostics, Inc. (England)
 Ortho-Clinical Diagnostics, Inc. (Raritan, NJ)
 Ortho-Clinical Diagnostics, Inc. (Rochester, NY)
 Oxoid Inc.
 Oxoid LTD (U.K.)
 Pfizer Inc
 Pharmacia & Upjohn
 Procter & Gamble Pharmaceuticals, Inc.
 The Product Development Group
 Quintiles, Inc.
 Radiometer America, Inc.
 Radiometer Medical A/S
 David G. Rhoads Associates, Inc.
 Rhône-Poulenc Rorer
 Roche Diagnostics GmbH
 Roche Diagnostics, Inc.
 Roche Diagnostic Systems (Div. Hoffmann-La Roche Inc.)
 Roche Laboratories (Div. Hoffmann-La Roche Inc.)
 The R.W. Johnson
 Pharmaceutical Research Institute
 Sanofi Diagnostics Pasteur
 Sarstedt, Inc.

SARL Laboratoire Carron (France)
 Schering Corporation
 Schleicher & Schuell, Inc.
 Second Opinion
 SenDx Medical, Inc.
 Showa Yakuhin Kako Company, Ltd.
 SmithKline Beecham Corporation
 SmithKline Beecham, S.A.
 Streck Laboratories, Inc.
 Sysmex Corporation (Japan)
 Sysmex Corporation (Long Grove, IL)
 The Toledo Hospital (OH)
 Vetoquinol S.A.
 Vysis, Inc.
 Wallac Oy
 Warner-Lambert Company
 Wyeth-Ayerst
 Xyletech Systems, Inc.
 YD Consultant

Trade Associations

Association of Medical Diagnostic Manufacturers
 Health Industry Manufacturers Association
 Japan Association Clinical Reagents Ind. (Tokyo, Japan)
 Medical Industry Association of Australia

Associate Active Members

20th Medical Group (Shaw AFB, SC)
 67th CSH Wuerzburg, GE (NY)
 121st General Hospital (CA)
 Acadiana Medical Laboratories, LTD (LA)
 Advocate Laboratories (IL)
 The Aga Khan University Medical Center (Pakistan)
 Allegheny General Hospital (PA)
 Allegheny University of the Health Sciences (PA)
 Allina Laboratories (MN)
 Alton Ochsner Medical Foundation (LA)
 Anzac House (Australia)
 Associated Regional & University Pathologists (UT)
 Aurora Consolidated Laboratories (WI)
 Baptist St. Anthony's Health Network (TX)
 Baystate Medical Center (MA)
 Brasileiro De Promocao (Brazil)

Bristol Regional Medical Center (TN)	Harris Methodist Northwest (TX)	Massachusetts General Hospital
Brookdale Hospital Medical Center (NY)	Hartford Hospital (CT)	MDS Metro Laboratory Services (Burnaby, BC, Canada)
Brooke Army Medical Center (TX)	Hays Pathology Laboratories, P.A. (KS)	MDS-Sciex (Concord, ON, Canada)
Brooks Air Force Base (TX)	Headwaters Health Authority (High River, AB, Canada)	Medical College of Virginia Hospital
Broward General Medical Center (FL)	Health Alliance Laboratory (OH)	Melrose-Wakefield Hospital (MA)
Calgary Laboratory Services (Calgary, AB, Canada)	Health Network Lab (PA)	Memorial Medical Center (LA)
Cardinal Glennon Children's Hospital (MO)	Health Sciences Centre (Winnipeg, MB, Canada)	Memorial Medical Center (IL)
Central Kansas Medical Center	Heartland Health System (MO)	Mercy Health System (PA)
Champlain Valley Physicians Hospital (NY)	Hinsdale Hospital (IL)	Mercy Hospital (NC)
Children's Hospital (LA)	Hoag Memorial Hospital Presbyterian (CA)	Methodist Hospital (TX)
Children's Hospital Medical Center (Akron, OH)	Holmes Regional Medical Center (FL)	Methodist Hospital Indiana
Clendo Lab (Puerto Rico)	Holy Spirit Hospital (PA)	Methodist Hospitals of Memphis (TN)
CLSI Laboratories (PA)	Holzer Medical Center (OH)	Mid Michigan Medical Center - Midland
Colorado Mental Health Institute at Pueblo	Hospital for Sick Children (Toronto, ON, Canada)	Milton S. Hershey Medical Center (PA)
Columbia Tulsa Regional Medical Center (OK)	Huddinge University Hospital (Sweden)	Mississippi Baptist Medical Center
Commonwealth of Kentucky	Hunter Area Pathology Service (Australia)	Monte Tabor-Centro Italo-Brazileiro De Promocao (Brazil)
CompuNet Clinical Laboratories (OH)	Hurley Medical Center (MI)	Montreal Children's Hospital (Canada)
Consolidated Laboratory Services (CA)	Instituto Scientifico HS. Raffaele (Italy)	Mount Sinai Hospital (NY)
Danville Regional Medical Center (VA)	International Health Management Associates, Inc. (IL)	National University Hospital (Singapore)
Dean Medical Center (WI)	Intermountain Health Care Laboratory Services (UT)	Naval Surface Warfare Center (IN)
Detroit Health Department (MI)	Jacobi Medical Center (NY)	Nebraska Health System
Duke University Medical Center (NC)	John Randolph Hospital (VA)	New Britain General Hospital (CT)
Durham Regional Hospital (NC)	Johns Hopkins Medical Institutions (MD)	New England Medical Center Hospital (MA)
Duzen Laboratories (Turkey)	Johnson City Medical Center (IN)	The New York Blood Center
Dynacare Laboratories - Eastern Region (Ottawa, ON, Canada)	Kaiser Permanente (CA)	The New York Hospital Medical Center of Queens
E.A. Conway Medical Center (LA)	Kenora-Rainy River Regional Laboratory Program (Dryden, Ontario, Canada)	New York State Department of Health
East Texas Medical Center	Klinicni Center (Slovenia)	NorDx (ME)
Elmhurst Memorial Hospital (IL)	LabCorp (NC)	North Carolina Laboratory of Public Health
Emory University Hospital (GA)	Laboratoire de Santé Publique du Quebec (Canada)	North Coast Clinical Laboratory, Inc. (OH)
Fairfax Hospital (VA)	Laboratório Fleury S/C Ltda. (Brazil)	Northridge Hospital Medical Center (CA)
Fairview-University Medical Center (MN)	Lancaster General Hospital (PA)	North Shore University Hospital (NY)
Foothills Hospital (Calgary, AB, Canada)	Langley Air Force Base (VA)	Northwestern Memorial Hospital (IL)
Fox Chase Cancer Center (PA)	Lewis-Gale Medical Center (VA)	Ohio State University Hospitals
Fresenius Medical Care/Life Chem (NJ)	Libero Instituto Univ. Campus BioMedico (Italy)	Olin E. Teague Medical Center (TX)
Fresno Community Hospital and Medical Center	Loma Linda University Medical Center (CA)	Our Lady of Lourdes Hospital (NJ)
GDS Technology, Inc (IN)	Los Angeles County and USC Medical Center (CA)	Our Lady of the Resurrection Medical Center (IL)
Grady Memorial Hospital (GA)	Louisiana State University Medical Center	Pathology and Cytology Laboratories, Inc. (KY)
Greater Southeast Community Hospital (DC)	Lutheran Hospital (WI)	
Guthrie Clinic Laboratories (PA)	Main Line Clinical Laboratories, Inc. (PA)	
Halifax Medical Center (FL)		
Harris Methodist Fort Worth (TX)		

Permanente Medical Group (CA)	Southern California Permanente Medical Group	VA (Kansas City) Medical Center (MO)
Presbyterian Hospital of Dallas (TX)	South Western Area Pathology Service (Australia)	VA Outpatient Clinic (OH)
Providence Health System (OR)	Speciality Laboratories, Inc. (CA)	VA (San Diego) Medical Center (CA)
Providence Medical Center (WA)	Stanford Health Services (CA)	VA (Tuskegee) Medical Center (AL)
Queen Elizabeth Hospital (Prince Edward Island, Canada)	Stormont-Vail Regional Medical Center (KS)	Vejle Hospital (Denmark)
Queensland Health Pathology Services (Australia)	Sun Health-Boswell Hospital (AZ)	Viridae Clinical Sciences, Inc. (Vancouver, BC, Canada)
Quintiles Laboratories, Ltd. (GA)	Sunrise Hospital and Medical Center (NV)	ViroLogic, Inc. (CA)
Regions Hospital	Sutter Health (CA)	Waikato Hospital (New Zealand)
Research Medical Center (MO)	Timmins & District Hospital (Timmons, ON, Canada)	Walter Reed Army Institute of Research (MD)
Riyadh Armed Forces Hospital (Saudi Arabia)	Tri-City Medical Center (CA)	Warde Medical Laboratory (MI)
Robert F. Kennedy Medical Center (CA)	Tripler Army Medical Center (HI)	Warren Hospital (NJ)
Saint Mary's Regional Medical Center (NV)	Trumbull Memorial Hospital (OH)	Washoe Medical Center (NV)
Santa Clara Valley Medical Center (CA)	Tulane Medical Center Hospital & Clinic (LA)	Watson Clinic (FL)
St. Alexius Medical Center (ND)	Twin Lake Regional Medical Center	Williamsburg Community Hospital (VA)
St. Anthony Hospital (CO)	UCSF Medical Center (CA)	Wilford Hall Medical Center (TX)
St. Boniface General Hospital (Winnipeg, Canada)	UNC Hospitals (NC)	Wilson Memorial Hospital (NY)
St. Francis Medical Center (CA)	Unilab Clinical Laboratories (CA)	Winchester Hospital (MA)
St. John Hospital and Medical Center (MI)	University of Alabama - Birmingham Hospital	Winn Army Community Hospital (GA)
St. John Regional Hospital (St. John, NB, Canada)	University of Alberta Hospitals (Canada)	Wishard Memorial Hospital (IN)
St. Joseph Hospital (NE)	University of Chicago Hospitals (IL)	Yonsei University College of Medicine (Korea)
St. Joseph's Hospital - Marshfield Clinic (WI)	University Hospital (IN)	York Hospital (PA)
St. Luke's Hospital (PA)	University Hospital (Gent) (Belgium)	Zale Lipshy University Hospital (TX)
St. Luke's Regional Medical Center (IA)	University Hospital (London, Ontario, Canada)	
St. Luke's-Roosevelt Hospital Center (NY)	University Hospital of Cleveland (OH)	
St. Mary Hospital (NJ)	The University Hospitals (OK)	
St. Mary Medical Center (CA)	University of Medicine & Dentistry, NJ University Hospital	
St. Mary Medical Center (IN)	University of Michigan	
St. Mary of the Plains Hospital (TX)	University of the Ryukyus (Japan)	
SARL Laboratoire Carron (France)	University of Texas Medical School at Houston	
San Francisco General Hospital (CA)	University of Virginia Medical Center	
Seoul Nat'l University Hospital (Korea)	University of Washington	
Shanghai Center for the Clinical Laboratory (China)	UPMC Bedford Memorial (PA)	
Shands Healthcare (FL)	USAF Medical Center (OH)	
SmithKline Beecham Clinical Laboratories (GA)	UZ-KUL Medical Center (Belgium)	
SmithKline Beecham Clinical Laboratories (WA)	VA (Dayton) Medical Center (OH)	
South Bend Medical Foundation (IN)	VA (Denver) Medical Center (CO)	

OFFICERS

William F. Koch, Ph.D.,
President
National Institute of Standards
and Technology

F. Alan Andersen, Ph.D.,
President Elect
Cosmetic Ingredient Review

Robert F. Moran, Ph.D.,
FCCM, FAIC
Secretary
mvi Sciences

Donna M. Meyer, Ph.D.,
Treasurer
CHRISTUS Health

A. Samuel Koenig, III, M.D.,
Past President
Family Medical Care

John V. Bergen, Ph.D.,
Executive Director

BOARD OF DIRECTORS

Sharon S. Ehrmeyer, Ph.D.
University of Wisconsin

Robert L. Habig, Ph.D.
Becton Dickinson and Company

Thomas L. Hearn, Ph.D.
Centers for Disease Control and
Prevention

Gerald A. Hoeltge, M.D.
The Cleveland Clinic Foundation

Elizabeth D. Jacobson, Ph.D.
FDA Center for Devices and
Radiological Health

Carolyn D. Jones, J.D., M.P.H.
Health Industry Manufacturers
Association

Hartmut Jung, Ph.D.
Roche Diagnostics GmbH

Tadashi Kawai, M.D., Ph.D.
International Clinical Pathology
Center

Barbara G. Painter, Ph.D.
Bayer Corporation

Marianne C. Watters,
M.T.(ASCP)
Parkland Health & Hospital
System

Ann M. Willey, Ph.D.
New York State Department of
Health

Judith A. Yost, M.A., M.T.
(ASCP)
Health Care Financing
Administration

Contents

Abstract.....	i
Committee Membership.....	v
Active Membership.....	vii
Foreword.....	xv
1 Introduction.....	1
1.1 Principle.....	1
1.2 Clinical Relevance.....	1
1.3 Clinical Use.....	3
1.4 Interpretation.....	4
2 Collection of Patient's Serum.....	5
2.1 Peak and Trough Levels.....	5
2.2 Sample Collection and Handling.....	5
2.3 Patient's Isolate.....	6
3 Serum Dilution Procedure.....	6
3.1 Broth Medium.....	7
3.2 Dilution Methods.....	8
3.3 Preparing Inoculum.....	9
3.4 Inoculating Broth.....	10
3.5 Incubation.....	10
3.6 Determining Endpoints.....	10
3.7 Interpretation of Bactericidal Dilution Titers.....	11
4 Area Under the Bactericidal-Titer Curve.....	11
5 Serum Bactericidal Rate.....	12
6 Antibiotic Carryover.....	13
7 Quality Control.....	13
7.1 Purpose.....	13
7.2 Selecting Reference Strains.....	13
7.3 Suggested Quality Control Strains.....	13
7.4 Batch or Lot Control.....	13
7.5 Other Control Procedures.....	13
Table 1. Rejection Value and Calculated Sensitivity and Specificity for Each Initial Concentration on the Basis of Duplicate 0.01-mL Samples.....	15
Table 2. Rejection Value and Calculated Sensitivity and Specificity for Each Initial Concentration on the Basis of a Single 0.01-mL Sample.....	16

Contents (Continued)

Table 3. Suitable Quality Control Ranges for MICs and MBCs With and Without Human Serum Using ATCC Strains.....	17
References	18
Additional References.....	21
Summary of Comments and Subcommittee Responses	22
Related NCCLS Publications	25

Foreword

All of the susceptibility test methods commonly performed by clinical microbiology laboratories (i.e., disk diffusion, broth dilution, and agar dilution) measure the inhibitory activity (MIC) of an antimicrobial agent.¹⁻³ In most clinical situations, this is sufficient as the role of the antibiotic is to prevent the spread of bacteria from the focus of infection by preventing microbial replication at new sites: the active participation of the host's defense mechanisms finally achieves bacterial eradication and clinical cure.⁴

On occasion, it may be necessary to achieve bactericidal activity with an antimicrobial agent. This need has been well documented for endocarditis⁵ and has been suggested by some for meningitis⁶ and for osteomyelitis⁷, as well as infections in immunocompromised patients.⁸

When assessment of bactericidal activity is deemed appropriate, an *in vitro* test method such as the MBC determination or the use of time-kill kinetic methodology may be useful. Bactericidal activity against the patient's isolate by the antibiotic tested allows eradication to be predicted based upon the usual dosing of this antibiotic or based upon the results of an antimicrobial assay. When clinical experience is lacking and assay methods are not readily available, the serum bactericidal test which integrates both pharmacodynamic and pharmacokinetic properties may be more useful. Depending on certain modifications to the serum bactericidal test, the test can provide a quantitative assessment of bactericidal activity relative to the MBC (the serum bactericidal titer), a dynamic assessment of rapidity of killing over time (the serum bactericidal rate), or both the magnitude of serum bactericidal activity and its duration (the area-under-the-bactericidal-titer-curve). In addition, methods using serum from persons (e.g., volunteers) receiving antibiotics (*ex vivo*) can be used to assess antimicrobial bactericidal activity across drug classes or between members of a class against a wide variety of microorganisms.

Because of the complexity involved with the serum bactericidal test (including the particular method used, the proper collection of timed serum specimens, and the interpretation of results), and the lack of clinical data clearly documenting the usefulness of this test for most infections, it is recommended that consultation with the microbiology laboratory be obtained as a prerequisite for this test. The assistance of the laboratory's director is useful in (1) determining if such a test is needed; (2) selecting NCCLS recommended methodology for testing; and (3) interpreting the results.

The clinical relevance of the serum bactericidal test remains controversial, and there are relatively few clinical situations in which the test is indicated. However, the serum bactericidal test is being used in volunteers as a tool in the evaluation of new antimicrobial agents. Whatever the reason for performing the serum bactericidal test, this document describes the details of the test and, in particular, describes the methodologic variations. This information has been obtained largely from published data. Use of these techniques should result in uniform methodology that is practical enough to be used in the clinical microbiology laboratory or in the research setting. The techniques are intended primarily for testing aerobic bacteria that grow well after overnight incubation in Mueller-Hinton broth.

In depth discussion of the factors influencing results of bactericidal tests and techniques for the conduct of MBCs and timed-kill studies may be found in the most current edition of NCCLS document M26–*Methods for Determining Bactericidal Activity of Antimicrobial Agents*.⁹

Standard Precautions

Because it is often impossible to know what might be infectious, all human blood specimens are to be treated as infectious and handled according to "standard precautions." Standard precautions are new guidelines that combine the major features of "universal precautions and body substance isolation" practices. Standard precautions cover the transmission of any pathogen and thus are more comprehensive than universal precautions which are intended to apply only to transmission of blood-

Foreword (Continued)

borne pathogens. Standard precaution and universal precaution guidelines are available from the U.S. Centers for Disease Control and Prevention (Guideline for Isolation Precautions in Hospitals, *Infection Control and Hospital Epidemiology*, CDC, Vol 17;1:53-80.), [MMWR 1987;36(suppl 2S):2S-18S] and (MMWR 1988;37:377-382, 387-388). For specific precautions for preventing the laboratory transmission of blood-borne infection from laboratory instruments and materials; and recommendations for the management of blood-borne exposure, refer to NCCLS document M29—*Protection of Laboratory Workers from Instrument Biohazards and Infectious Disease Transmitted by Blood, Body Fluids, and Tissue*.

Key Words

Schlichter test, serum bactericidal test, serum bactericidal titer, serum dilution test

Methodology for the Serum Bactericidal Test; Approved Guideline

1 Introduction

1.1 Principle

Bacterial eradication by antimicrobial therapy is determined both by the pharmacodynamic and pharmacokinetic properties of the antimicrobial agent(s) used.¹⁰

The pharmacodynamic properties of an antimicrobial agent are defined as its activity (inhibitory and/or lethal) against microbial pathogens. When this activity is evaluated over a time-concentration continuum, the lethal effect can be described either as concentration-dependent or time-dependent.

Concentration-dependent killing kinetics, as seen with aminoglycosides and fluoroquinolones, are those in which the rate of killing increases with increasing drug concentrations up to a point of maximum effect. In contrast, time-dependent killing kinetics, as seen with β -lactam agents and vancomycin, are those in which the rate of killing is relatively slow and continues only as long as the concentrations are in excess of the MIC.

Because both the magnitude and duration of the activity of the antimicrobial agent can be important in determining its bactericidal effect, the pharmacokinetic properties of the agent as well as the dosing parameters become important factors in determining the likelihood of bacterial eradication.

The usual *in vitro* susceptibility test methods such as the MIC-MBC determination or broth time-kill kinetic methodology do not consider the pharmacokinetic properties of the agent, but instead rely upon known pharmacokinetic properties with the usual dosing regimens. Often, an antimicrobial assay can provide the necessary pharmacokinetic data which can be combined with the susceptibility test result to allow one to predict bacterial eradication. For certain infections (such as endocarditis) requiring bactericidal activity, the serum bactericidal test is a method that considers both the pharmacodynamic and the pharmacokinetic properties of an antimicrobial agent and can

provide another predictive estimate of bacterial eradication.

The serum bactericidal test can be used to predict the margin of bactericidal activity relative to the MBC at the beginning and end of the dosing interval. It also can be used to measure duration of killing by serially determining the level of bactericidal activity and the area-under-the-bactericidal-titer-curve.¹¹ Lastly it can effectively assess the rapidity of killing in serum by measuring the killing effect over time.¹²

In a clinical setting, the peak and trough serum bactericidal titers are most easily determined and usually provide sufficient clinical information. In a research setting, the area-under-the-bactericidal-titer-curve and the serum bactericidal rate may be determined in addition to the serum bactericidal titer in order to provide a more comprehensive evaluation of the pharmacodynamics and pharmacokinetics of a new antimicrobial agent.

1.2 Clinical Relevance

It must be understood that, like most susceptibility tests, there is very little published information documenting the clinical relevance of the serum bactericidal tests.

The serum bactericidal test most often has been used to evaluate the therapeutic effectiveness of antimicrobial agents in bacterial endocarditis.^{13,14} In a comprehensive review of the literature covering the years 1948 to 1980, Coleman et al. were unable to find evidence that either the serum inhibitory or bactericidal titers had any prognostic value in the treatment of patients with endocarditis.¹⁵

However, evaluation of the serum bactericidal test in bacterial endocarditis is complicated by the fact that such patients receive four to six weeks of parenteral antimicrobial therapy and, for the most part, are cured by this regimen regardless of their serum bactericidal titers. For example, a multicenter collaborative study of infective endocarditis¹⁶ required seven years to acquire enough patients in the study to have statistically significant results, yet had only nine clinical failures. This same study found that

peak bactericidal titers of 64 or greater with the microdilution method were associated with 100% bacteriologic cure. The often-recommended peak serum bactericidal titer of 8 was not associated with predictive accuracy and had no statistically significant association with clinical cure. Finally, the results of the serum bactericidal test in this study were unable to accurately predict the failure of bacterial eradication.

The serum bactericidal test also has been used to monitor intravenous therapy followed by oral antimicrobial therapy for infective endocarditis, and the clinical outcome of these patients was excellent.¹⁷ The serum bactericidal test (both the serum bactericidal titers¹⁸ and the serum bactericidal rate¹⁹) have proven useful in animal models and in human therapy for assessing combination therapy of bacterial endocarditis.

The serum bactericidal test also has been used to monitor antimicrobial therapy in cancer patients. Klastersky et al.²⁰ measured the peak and trough levels of bacteriostatic and bactericidal activity of the serum and urine of 317 patients with cancer and a bacteriologically proven infection. When the serum bactericidal test had a peak titer of > 8 , the infection was cured in 80% of cases.

Similarly, Sculier and Klastersky⁸ analyzed the clinical significance of the serum bactericidal activity in cancer patients who presented with bacteremia caused by gram-negative bacilli. These investigators noted that the clinical response to antibiotic therapy in these patients strongly correlated with the peak serum bactericidal activity. Ninety-eight percent of nongranulocytopenic patients with a serum bactericidal titer of 8 or more had a favorable clinical response.

In contrast, patients with severe neutropenia (granulocyte count below $100/\text{mm}^3$) had an 87% rate of cure only with titers of 16 or more. The higher titers needed with neutropenic patients may be related to the need for bactericidal activity over a longer time span. A 16-peak serum bactericidal titer guarantees some bactericidal activity in the serum for four half-lives of the drugs being tested. Drusano et al.²¹ have found that four of five neutropenic patients with gram-negative bacteremia in whom empiric combination therapy failed had no bactericidal titers at trough levels.²¹ This is

in distinct contrast to the 21 patients who survived, all having measurable serum bactericidal titers at trough levels.

The serum bactericidal test appears to have utility in some cases for predicting bacterial eradication in patients with skeletal infections. Osteomyelitis and suppurative arthritis remain difficult to treat successfully despite the availability of effective antimicrobial agents. Dich et al.,²² for example, found that 19% of children whose antibiotic regimen was changed from parenteral to oral during the first three weeks of treatment had relapses or their infection took on a chronic course.

This is in contrast to the cumulative experience of other investigators who have used the results of the serum bactericidal test to adjust the therapy of children receiving parenteral followed by oral antimicrobial therapy. Tetzlaff and colleagues²³ treated 30 children with acute hematogenous skeletal infections (19 osteomyelitis, 3 osteoarthritis, and 8 suppurative arthritis) with a brief (1 to 13 days) period of parenteral antibiotic therapy followed by oral therapy to complete a usual 4-week course. Adjustments in dosage were made when necessary to insure a peak serum bactericidal titer of at least 8. Twenty-nine of thirty were successfully treated.

Kolyvas et al.²⁴ also used the serum bactericidal test to monitor parenteral/oral therapy in children, adjusting doses of antibiotics to achieve peak titers of 1:8. All of 10 children studied remained cured after follow-up of one year. Prober and Yeager²⁵ reported the results of 22 children treated with sequential therapy of intravenous followed by oral agents. Peak serum bactericidal titers of 8 were achieved in 21 of the 22 patients; trough titers of 2 in 20 of 22 patients. The authors had no recurrences in 21 of 22 patients.

Finally, Syrogiannopoulos and Nelson²⁶ reviewed ten years of experience with children who had acute suppurative osteoarthritis. There were 180 children who received large doses of oral antibiotics following clinical stabilization with intravenous antibiotics; the median duration of intravenous therapy was about one week. Serum bactericidal titers were used routinely to monitor absorption and determine an adequate dose. These investigators used a peak serum bactericidal titer of 1:8 when the

pathogen was a gram-negative bacillus, *S. aureus*, or *H. influenzae* and at least 1:32 when the etiologic agent was a streptococcus. If the titers were suboptimal, the dosage of the antibiotic was increased. The dosages of oral antibiotics used under these guidelines were two-to-three times those normally used.

Over this ten-year period, no patient with suppurative arthritis was readmitted with recurrence. Four patients with acute osteomyelitis were readmitted with recurrence, representing 3.8% of the 106 patients with bone infection. In two of these recurrences, noncompliance with the oral therapy (one case proven and one suspected) were felt to be the reason for antimicrobial failure.

In a retrospective report of 18 adults with osteomyelitis, Black et al.²⁷ assessed the plausibility of sequential parenteral-peroral antimicrobial therapy, adjusting the trough titer on peroral therapy to >1:8. There were 16 out of 18 patients who were cured.

In another study with mostly adults, Weinstein et al.⁷ prospectively assessed the value of serum bactericidal titers to predict outcome of patients with acute and chronic osteomyelitis. These investigators analyzed 51 patients with osteomyelitis, 30 acute and 21 chronic, who were monitored at multiple medical centers with the same serum bactericidal test methodology.

In this series, trough serum bactericidal titers of 1:2 or greater predicted medical cure in 23 of 25 patients successfully treated for acute osteomyelitis. There were 13 successfully treated episodes out of 21 cases of chronic osteomyelitis. In these 13 patients, peak serum bactericidal titers of 1:16 or greater and the trough titers of 1:4 or greater were achieved and accurately predicted a cure. In contrast, peak titers of less than 1:16 and trough titers of less than 1:2 in the 8 patients in whom therapy failed accurately predicted this failure.

Other investigators reported that one should aim for trough values of 1:2 or greater, whenever possible.²⁸ However, if the patient response is favorable, dosage should not be altered.

1.3 Clinical Use

It must be recognized that the number of clinical situations in which a serum bactericidal

test is needed is very limited. There are, however, theoretical situations in which the serum bactericidal test might be useful.

The serum bactericidal titer, for example, can be used to determine the magnitude of serum bactericidal activity in relation to the MBC. This parameter can be important for antimicrobial agents that exhibit concentration-dependent killing kinetics as shown by Moore and colleagues²⁹ who have reviewed the clinical course of 236 patients with gram-negative bacillary infections that were treated with aminoglycosides. The clinical response to aminoglycosides in these patients was 80% (188 patients). Elevated maximal and mean peak aminoglycoside concentration/MIC ratios were strongly associated with clinical response ($P < 0.0001$ and $P < 0.00001$, respectively). By logistic regression the peak concentration/MIC ratios were associated significantly with clinical response after adjustment for underlying severity of disease and other factors correlated with response. The serum bactericidal test, conceptually, measures no more than the serum level of the antimicrobial agent divided by the MIC or MBC of the infecting organism.³⁰

NOTE: This statement is generally true providing there is no chemical, ionic binding, or pharmacologic interference with drug activity.

There are some conditions where drug concentration does not reflect drug activity. Although for aminoglycosides the availability of assay methods for determining the peak levels precludes the need for the serum bactericidal test, the serum inhibitory activity for peak levels of aminoglycosides, in theory, should be useful in predicting clinical response in patients with gram-negative bacillary infections who are treated with aminoglycosides. There are no currently available assay methods similar to those available for aminoglycosides for fluoroquinolones. Fluoroquinolones are also concentration-dependent agents. Determination of serum bactericidal titers therefore may be useful in intravenous therapy with ciprofloxacin so as to avoid clinical failure as has been reported for seven of ten patients with nosocomial pneumonia caused by *P. aeruginosa* who were treated with intravenous ciprofloxacin.³¹

Moore and colleagues also noted that high plasma levels of aminoglycosides are associated

with decreased mortality in patients with gram-negative bacillary pneumonia.³²

For antimicrobial agents that exhibit time-dependent killing kinetics, a trough serum bactericidal titer would, in theory, be useful to demonstrate that the serum concentration-time profile has free drug levels always remaining above the MIC (e.g., four-to-eight times the MIC) for the duration of time prior to the next dose. The clinical relevance of such an approach can be seen in the study of Warren et al.³³ who found that the efficacy of cefoperazone correlated best with the trough concentration of free drug being above the MIC of the infecting isolate.

The serum bactericidal test can also be used to measure not only the magnitude of serum bactericidal activity but also its duration. This is done by plotting serum bactericidal titers measured over time and calculating the area under the curves. The largest area under the bactericidal-titer curve will be found for the antimicrobial agent(s) with the best combination of three factors: antibacterial activity, achievable free drug concentrations, and half-life.¹¹

Barriere et al.³⁴ serially determined the serum bactericidal activity of three new cephalosporins and found prolonged bactericidal activity against *E. coli* for cefotaxime despite the half-life of this agent being only 1 hour. The authors postulated that the unexpected prolonged bactericidal activity was likely due to the presence of the active metabolite, desacetylcefotaxime, and suggested that a dosage of 1 g of cefotaxime every 8 to 12 hours should be sufficient for infections caused by susceptible gram-negative bacilli. The efficacy of this dosing schedule subsequently has been confirmed by the clinical study by Goodpasteur et al.³⁵ The area under the bactericidal-titer curve provides another dimension to the evaluation of investigational antibiotics.

The serum bactericidal titer, like the MBC, determines bactericidal activity after 24 hours of incubation and separates the bacteria into two populations, a segregation that might not have biological relevance. The serum bactericidal rate, however, evaluates the rapidity of bacterial killing and has been shown in an experimental animal model to correlate

better with the rapidity of sterilization of vegetations and to reflect the concentration dependency of the synergy of nafcillin plus an aminoglycoside against *S. aureus*.^{19,36,37}

In human volunteers, Van der Auwera et al.³⁸ compared the serum bactericidal rates for imipenem and vancomycin against methicillin-susceptible and methicillin-resistant *S. aureus*. These investigators found that against methicillin-susceptible *S. aureus* isolates, imipenem and vancomycin provided an equivalent rate of killing. Against methicillin-resistant isolates, imipenem was almost equivalent to vancomycin. The relevance of these findings is suggested by Fan et al.³⁹ who studied the clinical efficacy of imipenem against methicillin-susceptible and methicillin-resistant *S. aureus*. Eleven of 12 methicillin-susceptible and 10 of 11 methicillin-resistant *S. aureus* infections were clinically cured. This method for evaluating the serum bactericidal rate is worthy of further investigation as a tool for the evaluation of new antimicrobial agents.

1.4 Interpretation

The relation of the test results of the serum bactericidal test to the clinical outcome is not such that cure or failure can be predicted easily.⁴⁰ Bactericidal activity is only one factor in the treatment of infected patients. It is important to understand the difference between bacterial eradication and clinical cure. Obviously, the ultimate clinical cure cannot be predicted accurately solely by an *in vitro* test of antimicrobial activity. Clinical cure depends largely upon host factors and other factors, e.g., postantibiotic effect and the growth-inhibitory effects of sub-MIC concentrations of antibiotics may also impact bacteriologic response of patients.⁴¹

Most immunocompetent hosts with bacterial infections, moreover, do not require antimicrobial therapeutic programs in which there is bactericidal activity. Strict adherence to the achievement of an arbitrary serum bactericidal activity in the absence of supporting data may create an increased risk for the patient. For example, drug toxicity might ensue due to an unnecessary increase in dosage in a clinically stable patient with a low titer.

Conversely, an effective dose may be lowered inappropriately. It is also important to realize

that the final result of the serum bactericidal test can be greatly influenced by methodology. Many factors must be carefully controlled if reproducible results (intralaboratory and interlaboratory) are to be achieved. Because of the specialized nature, the variations of methodology, the need for timed specimens, the complexity of technical factors, and the potential difficulty for interpretation, it is recommended that the serum bactericidal test be done in consultation with the director of the clinical microbiology laboratory (i.e., this test should be performed in reference or research laboratories or those laboratories with highly-trained medical technologists).

With such assistance, the clinician can more easily determine if the serum bactericidal test is the appropriate test for assessing bactericidal activity for his patient, determine which variation is most appropriate, assure that the serum specimens are collected properly, and properly interpret the results.

2 Collection of Patient's Serum

2.1 Peak and Trough Levels

Generally, both a peak and trough level are obtained with the serum bactericidal test. The optimal timing of samples and most appropriate storage conditions for collecting and obtaining peak levels varies by drug and by route of administration; therefore, the product labeling should be consulted to select the optimal sampling times.

This timing attempts to ensure that the peak level is obtained approximately 30 to 60 minutes after the antimicrobial agent is absorbed and distributed. The trough level is that level obtained immediately before the next dose.

These definitions are useful for single antimicrobial agent therapy and are based on the usual pharmacokinetic properties of antimicrobial agents. If more than one antibiotic is being used, the peak sample should be obtained 1 hour after administration of the second antibiotic. If one of the agents is administered infrequently (e.g., every 12 hours) and the other is administered more frequently (e.g., every 4 hours), peak levels should be obtained 1 hour after completion of the infusion of the second antimicrobial agent at a time

when the administration of both antimicrobial agents coincides. Though levels may be obtained based on the timing of the less frequently administered agent, the assumption is made that the agent administered every 4 hours will have a more constant level.

2.2 Sample Collection and Handling

The serum specimen must be collected aseptically. Any bacterial contamination from the skin may interfere with the results. Also, because of short half-lives of some antibiotics, the timing of the serum collection is critical, and the time the antimicrobial agent was given should be confirmed. This should include:

- The time that the previous dose was given.
- The time that the current dose was given or will be given.
- The duration of the infusion when obtaining peak levels for intravenously administered agents.

Antimicrobial agents may not be given at the exact times ordered on a busy nursing unit, and care must be taken to ensure that peak and trough specimens are obtained accurately. Some hospitals designate one person to collect all samples for any type of drug assay. Specimens should be clearly marked with the following:

- Patient's name and hospital number.
- Antimicrobial agent(s) and dose(s) being used.
- Time of antimicrobial dose (start and completion of infusion) and initials of medication nurse.
- Time and date of specimen collection and initials of collector.

One method to ensure compliance with proper collection is to require that the above material be completed on a requisition slip by the appropriate persons (medication nurse and blood collector) and initialed. If the requisition slip is not properly completed (with initials), the specimen is not processed. After the specimen has been collected, serum should be separated from red blood cells as soon as possible. Rapid

transportation to the laboratory is necessary; if any delay is expected, the specimen (blood or serum) should be transported on ice. (Serum must be frozen if the tests are to be delayed more than 2 hours; blood cells must be separated first because freezing hemolyzes the red blood cells.) Adhere to the pharmaceutical manufacturer's guidelines for stability of the antibiotic in frozen human serum prior to testing. If serum is submitted frozen to a reference laboratory for SBT testing, send in a sterile plastic vial. Do not use glass.

2.3 Patient's Isolate

The patient's isolate must be saved to serve as the inoculum. The isolate may be kept frozen at -70°C in tryptic soy broth or in a glycerol suspension of a subculture on a tryptic soy agar slant. It is advisable to subculture the isolate three times before testing to ensure that the organism has an optimal growth and metabolic status before the drug exposure.

Since variations in density of inoculum may alter the endpoints by one or more dilutions, the correct preparation of a standardized inoculum is critical. The rate of loss of viability of

bacterial cells following exposure to most antibiotics is a direct function of bacterial growth prior to the addition of the agent with especially marked effect shown for cell-wall-active agents. The use of stationary phase cultures, such as recently inoculated cultures growing for periods >8 hours, will include an increased number of dormant cells which are not susceptible to the agent and, therefore, cause diminished killing rates. See references and text in the most current edition of NCCLS document M26—*Methods for Determining Bactericidal Activity of Antimicrobial Agents*.

In addition, the use of a lag phase cultures, i.e., cultures which have recently undergone a change in test condition (e.g., temperature shift or change from agar to broth medium), will also include cells less reactive to the agent and, therefore, cause less reliable killing endpoints (see Figure 1). A higher inoculum size, even in log phase cultures, will approach the stationary growth phase and such organisms may be killed more slowly.




Figure 1. Bacterial Growth Curve. Growth curve of typical bacterial culture as measured by viable count (a: Lag phase; b: logarithmic phase; c: stationary phase; d: death phase).

3 Serum Dilution Procedure

The method for determining serum bactericidal titers is a variation of the broth dilution test, and many of the methods used to control the variables in the broth dilution test are applicable to the serum dilution procedure. Hence, it is

advisable to refer to extensive discussions, particularly of biological and technical factors influencing test interpretation in NCCLS document M26—*Methods for Determining Bactericidal Activity of Antimicrobial Agents*.

3.1 Broth Medium

3.1.1 Human Serum as Diluent

In the serum bactericidal test, a broth is used to dilute the patient's serum. Many different broths have been used as diluents, including trypticase soy, brain heart infusion, Columbia, dextrose phosphate, and (most commonly) Mueller-Hinton.⁴¹ The use of salt-containing diluents must be avoided when testing staphylococci and β -lactam agents. Human serum in a 1:1 ratio (CAMHB/HS) has also been recommended as the diluent.⁴² The main rationale for human serum as a diluent is to assess the role of protein-binding in the results.^{30,42,43} Although the *in vitro* effects of protein-binding are well known,^{44,45} there has been debate as to the clinical relevance of this phenomenon. There is information available, however, as to the importance of protein-binding in determining clinical cure.

Chambers et al.⁴⁶ found that cefonicid, a highly protein-bound cephalosporin, failed to clear the blood of bacteria or to produce a resolution of clinical findings by day five of therapy in three of four patients with staphylococcal endocarditis. This was despite peak concentrations that were assayed in two patients and found to be 20 to 40 times the MIC for the infecting isolate. However, when protein was added to the medium, MICs for the isolates rose four-to-eightfold and bactericidal titers were < 1:8 at peak for all three patients.

In another study evaluating a highly protein-bound antimicrobial agent (teicoplanin), Calain and colleagues⁴⁷ described six failures despite measured trough concentrations of total teicoplanin which exceeded the MIC for the infecting pathogen by 5 to 35 times in four of these patients. Because teicoplanin is very highly protein-bound, free antimicrobial agent was noted to be less than the MIC even at peak concentrations. Bolivar et al.⁴⁸ evaluated cefoperazone (12 g/day) as single agent therapy in cancer patients. These investigators were able to achieve success in 80% (44 of 55) of cases where the MIC of cefoperazone was \leq 25 μ g/mL for the infecting organism.

Based on these clinical observations, Peterson et al.⁴⁹ have used pharmacokinetic concepts to predict what a 12-g/day dose of cefoperazone would produce in terms of extravascular levels

of cefoperazone. They predicted that such a dose would result in extravascular levels of free cefoperazone in the range of 15 to 25 μ g/mL. (Total mean levels in serum would be expected to range from 75 to 250 μ g/mL.) This correlates very nicely with the clinical observations of Bolivar. Clearly, the clinical importance of protein-binding can be demonstrated for both gram-positive and gram-negative organisms.

Despite the theoretical and proven importance of using human serum as the diluent, there is a multitude of problems associated with the use of pooled human serum in the clinical microbiology laboratory. This problem can be avoided simply by using an ultrafiltrate of the patient's serum.⁵⁰ This separates the free antimicrobial agent present and allows the use of Mueller-Hinton broth as the diluent. The use of an ultrafiltrate in the measurement of serum bactericidal activity avoids the disadvantages associated with the use of normal pooled human serum for the diluent. Ultrafiltration of serum is easily accomplished by centrifugation at 25 °C for 30 minutes at 1000 x g using a commercially available filtration device. Sterilization of the ultrafiltrate is done by filtration through a 0.2-micron filter.

For antimicrobial agents that are known to have relatively little protein binding (<90%, e.g., gentamicin and vancomycin), Mueller-Hinton broth can be used as the diluent. If there is appreciable protein-binding (>90%, e.g., ceftriaxone and nafcillin), then either an ultrafiltrate of the patient's serum or the use of pooled human serum as the diluent is recommended. Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) of most antimicrobial agents determined with and without human serum against strains of bacteria commonly used as quality controls in susceptibility testing can be useful for quality control measures (see Table 3).⁵¹

3.1.2 Broth Monitoring

The performance and chemical characteristics of both Mueller-Hinton broth and human serum must be routinely monitored.

- The pH of each batch of Mueller-Hinton broth should be checked with a pH meter

when the medium is prepared; pH should be between 7.2 and 7.4.

- The MIC characteristics of broth should be evaluated periodically with a standard set of quality control microorganisms and with an antibiotic from each major class. The frequency of such testing will depend on the overall quality control program and the volume of serum bactericidal tests done.

MICs for aminoglycosides and fluoroquinolones tested in Mueller-Hinton (MH) broth may be lower than MICs obtained on MH agar (particularly when *Pseudomonas aeruginosa* is tested) unless the MH broth is adjusted to contain the recommended concentrations of Ca^{+2} and Mg^{+2} .

Pooled human serum can be obtained from commercial sources or from volunteers. It must be quality controlled as rigorously as any other reagent used in a clinical microbiology laboratory. For the safety of laboratory personnel, it should be screened for hepatitis B virus antigen and for antibodies to HIV-1. (The pooled human serum may be heated to 56 °C for 1 hour upon receipt to inactivate HIV-1 and complement.) Next, the serum should be adjusted with 0.1 N NaOH or 0.1 N HCl to pH 7.2 to 7.4. After adjustment of pH, the serum should be clarified by prefiltering with a 0.80-micron filter. Finally, the serum should be filtered using a 0.22-micron filter.

Pooled human serum may contain substances to neutralize antibiotic agents, e.g., β -lactamases. For this reason, pooled human serum should be tested for the presence of β -lactamase activity especially when β -lactamases are to be tested. There are several commercially available rapid β -lactamase tests. Any of these, except those utilizing PADAC⁵² can be used by dropping some of the sera on the test strip and observing for a color change over 30 minutes. The serum should be screened for nonspecific antimicrobial activity by putting 20 μL of the pooled human serum on blank paper disks, placing the disks onto nutrient agar that has been seeded with a spore suspension (5×10^8) of *Bacillus subtilis* ATCC® 6633, and looking for zones of inhibition after incubation at 35 °C for 24 hours.

A final quality control measure is to periodically determine MICs and MBCs of various

antimicrobial agents for control strains of bacteria in media supplemented with the serum.

Use one antibiotic from each major class (penicillins, cephalosporins, and aminoglycosides) against an appropriate ATCC strain (see Section 7.3). MICs and MBCs of many antimicrobial agents have been determined with and without human serum against strains of bacteria commonly used as quality controls in susceptibility testing.⁵¹ The pooled human serum should be heated to 56 °C for 1 hour just before use in order to inactivate HIV-1 and any complement. The serum may be stored at -20 °C or less until needed.

3.2 Dilution Methods

Inhibitory activity is determined by dilution methods similar to those used to determine an MIC. Dilutions having no visible growth can then be sampled with a calibrated device to determine the concentration at which 99.9% of the final inoculum is killed.

Serum bactericidal titers can be determined with:

- A macrodilution method (1 to 2 mL in each test tube).
- A microdilution method (100 μL in each well).

It can be difficult to determine 99.9% killing of the final inoculum with the microdilution method. However, the microdilution method has been found to be more reproducible than the macrodilution method for bactericidal testing.^{51,53-60} Clinical studies suggest, moreover, that the microdilution method is useful.^{7,8,10} It also is better suited for research purposes when testing serum from volunteers receiving antibiotics against large numbers of different isolates. Therefore, the microdilution method is recommended for the serum bactericidal test.

3.2.1 Macrodilution Method

The macrodilution method, if done, should be performed in sterile 13- x 100-mm acid-treated borosilicate glass test tubes. (Bacteria adhere to the walls of plastic tubes.) The following procedure is similar to that for MIC determinations.

- (1) Add 1.0 mL of the patient's serum to each of the first two tubes. Alternatively, use 1.0 mL of an ultrafiltrate of the patient's serum.
- (2) Add 1.0 mL of heat-inactivated pooled human serum to tubes 2 through 10. Alternatively, use cation-adjusted Mueller-Hinton broth (CAMHB).
- (3) Make serial two-fold dilutions beginning with the second tube and continuing through the ninth tube, leaving an intermediate volume of 1.0 mL in each tube (use a separate pipette for each tube). Make the dilutions by withdrawing 1.0 mL from the tube containing 2.0 mL and transferring this to the next tube which is then mixed on a vortex mixer before the next step is repeated.
- (4) After the dilutions have been completed, add 1.0 mL of CAMHB, or other broth (if necessary) to each tube in order to yield a final volume of 2.0 mL in each tube, ending with a 1:1 ratio of pooled human serum to broth.
- (5) Use the tenth tube as a control for growth of the organism.

3.2.2 Microdilution Method

The preferred microdilution method is performed in sterile plastic microdilution trays that have round or conical bottom wells, each containing a final volume of 0.1 mL of broth. Adherence of bacteria to the sides of the wells has not been found to be a problem as has been found with the use of plastic test tubes for the macrodilution method. The micro-dilution method is simple and more efficient, and requires less broth. The following procedure is similar to that for MIC determinations.

- (1) Add 0.05 mL of pooled human serum or CAMHB to each well of columns 2 through 10 in each row.
- (2) Add 0.05 mL of the patient's serum or serum ultrafiltrate to each of the first two wells.
- (3) Make serial two-fold dilutions of the serum from column 2 through column 9 with a

semiautomatic microdiluting device employing 0.05-mL microdiluters.

- (4) Use the tenth well as a positive growth control.

3.3 Preparing Inoculum

The patient's isolate is used to prepare the inoculum. Variations in density of inoculum may alter the endpoints by one or more dilutions, and therefore, the preparation of a standardized inoculum is critical.

- (1) To address the possibility of heterogeneously distributed resistance among colonies, prepare the standardized final inoculum by using 5 to 10 colonies of a single type from a 16- to 24-hour agar plate containing nonselective culture medium; inoculate them into a tube containing 5.0 mL of prewarmed (35 °C) broth (i.e., CAMHB or trypticase soy broth).
- (2) Incubate this bacterial suspension at 35 °C until it is visibly turbid (up to six hours for staphylococci; gram-negative rods may require < six hours). Log-phase inocula should be prepared in a shaker-incubator and flask or beaker, whenever possible, to promote uniformity and optimization of growth.
- (3) Adjust the turbidity of the actively growing broth culture (logarithmic phase) to obtain a turbidity visually comparable to that of a 0.5 McFarland turbidity standard.
- (4) Dilute the adjusted culture in broth (macrodilution method) or 0.9% buffered saline (microdilution method) so that after inoculation of drug-containing broths, each tube or well contains 5×10^5 CFU/mL.

The number of CFU/mL in the broth medium just before incubation is known as the final inoculum. The inoculum size of the final inoculum must be determined by serial dilution in saline and subculture to solid media for use the next day to interpret killing endpoints. The exact inoculum volume delivered to the tubes or wells must be known before this calculation can be done. For example, if the volume of medium in the tubes is 2.0 mL, and the inoculum is 0.1 mL, the adjusted culture (1.5×10^8 CFU/mL)

must be diluted 1:20 with broth to yield 7.5×10^6 CFU/mL. When 0.1 mL of this suspension is inoculated into 2.0 mL of the broth, the final inoculum of bacteria will be approximately 4×10^5 CFU/mL.

Count the viable colonies in the inoculum to verify the final inoculum size. (This can easily be done by using the growth control test tube or by using a second growth control well in the microdilution plate.) This is accomplished by using a micropipettor to drop a 10^{-2} , 10^{-3} , and 10^{-4} saline dilution of the inoculum onto the surfaces of agar plates and then spreading this over the surface. (The micropipettor volume should be ≤ 0.1 mL.) After overnight incubation, the plate showing 20 to 200 colonies is used to calculate the initial inoculum size. For example, if there are 40 colonies on the plate inoculated with the 1:1000 dilution, then the final inoculum contained 4×10^5 CFU/mL.

3.4 Inoculating Broth

3.4.1 Macrodilution Method

Prepare the dilutions of the patient's serum before adjusting the actively growing inoculum. Within 15 minutes after the inoculum has been standardized, add 0.1 mL of the adjusted inoculum to each tube in the dilution series with a micropipettor to release the inocula beneath the surface of antimicrobial-containing solution.

Mix by flushing two or three times without creating air bubbles or splashing the sides of the tubes. Do not vortex or agitate the tubes.

3.4.2 Microdilution Method

As in the macrodilution method, make the dilutions before adjusting the actively growing inoculum. Then, dilute the inoculum and use to inoculate the solution within 15 minutes after the inoculum is standardized. If the volume of the inoculum exceeds 10% of the well volume, the diluting effect of the inoculum on the antimicrobial agent must be taken into account. If a 0.05-mL pipette dropper is used to add inoculum to the wells, the resulting dilution is 1:2 which results in a final range of dilutions of the patient's serum of 1:2 to 1:512.

An alternative way to inoculate the wells is to first add 0.05 mL of broth to each well after the dilutions of the serum have been made and then add 0.0015 mL of inoculum with a multipoint

inoculator and a seed tray. In this case, the number of organisms in the seed tray should be determined and must be at least 5×10^7 CFU/mL. To prevent evaporation during incubation, seal each tray in a plastic bag, with plastic tape or with a tight-fitting plastic cover before incubation.

3.5 Incubation

For all test methods, incubate the tubes or trays at 35 °C in air or CO₂, if required for growth of the patient's isolate. Macrodilution tubes should be incubated for 20 hours, vortexed, reincubated, and then vortexed again before sampling at 24 hours. Microdilution trays should be incubated for 24 hours and should be shaken at 20 hours but *not* before sampling at 24 hours. To maintain the same incubation temperature for all cultures, do not stack microdilution trays more than four high.

3.6 Determining Endpoints

The commonly used definition of serum bactericidal activity is 99.9% killing ($\geq 3 \log_{10}$ drop in CFU/mL) of the original inoculum. The final inoculum size must be known. The volume subcultured must be based on this final inoculum size and must be done quantitatively. Because of inaccuracy due to random variation in the number of cells in a small-volume sample, this subculture volume should be large enough to provide an endpoint of at least ten colonies, but not so large that the antimicrobial agent is carried over in a concentration high enough to continue inhibition of viable cells. Methods for determining MBCs which take into account pipetting error and intrinsic sampling variability due to the Poisson distribution of sample response have been described.⁵⁰⁻⁵⁷

In these techniques, the final inoculum size can be determined by a method such as the surface-drop count⁵⁸ or by a quantitative subculture using a calibrated pipettor.⁵⁰ Rejection values are determined by a chart that considers the final inoculum size, single or double sampling, pipetting error, and the Poisson distribution of sample responses (Tables 1 and 2 contain the rejection values, i.e., the threshold for assessing lethal activity, for single and duplicate 0.01-mL sampling with a 5% pipette error⁵⁰). The calculated sensitivity and specificity for these rejection values are

provided for the sake of completeness. (See footnote (a) in Table 2.)

3.6.1 Macrodilution Endpoints

Determine macrodilution endpoints as follows:

- (1) Use a logarithmic-phase culture for the final inoculum.
- (2) The final inoculum should be 5×10^5 CFU/mL (range $\geq 1 \times 10^5$ CFU/mL to $\leq 1 \times 10^6$ CFU/mL).
- (3) Confirm the final inoculum (5×10^5 CFU/mL) by actual count of CFUs.
- (4) Add the final inoculum to the tubes in small volume (0.1 mL) below the surface, with no shaking.
- (5) Gently mix by hand (or vortex at a low speed) at 20 hours and again at 24 hours before sampling.
- (6) Use a 0.01-mL calibrated pipettor to subculture each clear test tube; duplicate subcultures should be done.
- (7) Streak the broth subcultured on an agar plate. The number of colonies subsequently grown after 48 hours of incubation is used to determine the lethal endpoint based on the final inoculum and the rejection values. For example, if the final inoculum is 5×10^5 and a single sample is used, the dilution having fewer than 11 colonies is the lethal endpoint (Table 2).
- (8) The dilution which demonstrates 99.9% killing of the final inoculum is the bactericidal dilution titer.

3.6.2 Microdilution Endpoints

- (1) Use a logarithmic-phase culture for the final inoculum.
- (2) The final inoculum should be 5×10^5 CFU/mL (5×10^4 CFU/well) (range: 1×10^5 to 1×10^6 CFU/mL).
- (3) Confirm the final inoculum (5×10^5 CFU/mL) by actual count of CFUs.

- (4) The final inoculum can be added to the wells in a volume equal to half the final volume or can be added using a multipoint inoculator (0.0015 mL). Do not shake.
- (5) A multipoint inoculator or a pipettor can be used to remove 10 μ L; duplicate subcultures should be done.
- (6) Spot the broth subcultured with the multipoint inoculator on an agar plate with the first *no growth* after 48 hours of incubation being considered the lethal endpoint. Alternatively, streak the broth subcultured on an agar plate and after 48 hours of incubation, count the colonies and use the rejection values in Tables 1 and 2. Colonies should not be counted when the 10 μ L is spotted on an agar plate due to the tendency for the colonies to run together.
- (7) The dilution which demonstrates 99.9% killing of the final inoculum is the bactericidal dilution titer.

3.7 Interpretation of Bactericidal Dilution Titers

Although interpretation of the bactericidal dilution titers is controversial based on the limited number of clinical evaluations, the following are "approximate" guidelines for the clinical laboratory that uses the microdilution methodology delineated herein. As a general guideline, SBTs of 16 to 32 were frequently associated with more favorable clinical outcomes in patients with endocarditis.^{7,8,28} The peak SBT has been predictive of favorable outcome for some patients with skeletal infections although some investigators have indicated that trough SBTs of 2 or greater may be more predictive.

Inability to achieve a specific titer without toxic levels of the antimicrobial agent(s) may indicate the need for alternative agents. Lastly, the medical literature should be followed for other applications and validations.

4 Area Under the Bactericidal-Titer Curve

The area under the bactericidal-titer curve is determined by plotting bactericidal titers

measured over time and calculating the area under the curve. The resulting area under the bactericidal-titer curve serves as a unifying value to measure not only the magnitude of serum bactericidal activity but also its duration. The largest area under the bactericidal-titer curve is found for the antimicrobial agent with the best combination of three factors: antimicrobial activity, achievable free-drug concentration, and half-life. The individual serum bactericidal tests which are performed over time are done as described in Section 3. This technique is generally reserved for research as a means of comparing different antimicrobial agents or combinations of agents.

5 Serum Bactericidal Rate

The serum bactericidal rate evaluates the rapidity of bacterial killing over time. The serum bactericidal rate is performed by first obtaining peak and trough serum samples which are then processed to yield ultrafiltrate. The ultrafiltrate is filter-sterilized and then mixed with an equal volume of CAMHB to yield a 1:2 dilution. A total volume of 10 mL is used with a glass test tube. The inoculum is added in a small volume below the surface with a micropipettor in order to avoid splashing on the inside of the test tube above the meniscus. The final inoculum should be approximately 5×10^5 CFU/mL and confirmed by a colony count. Test tubes should not be agitated during incubation, but should be vortexed after each sampling.

One test tube is used as a growth control and consists of the same inoculum added to CAMHB. The final inoculum is confirmed at time 0; subsequent colony counts are done at 4 hours, between 6 and 12 hours, and at 24 hours. Sampling for colony counts is done by removing 0.5-mL samples of the broth at the specified times. The 0.5-mL sample is serially diluted in test tubes containing 4.5 mL of buffered sterile saline (0.9% NaCl) to produce tenfold dilutions (10^{-1} , 10^{-2} , 10^{-3} , 10^{-4}). A number of different colony count methods can be used to determine the CFU/mL from these dilutions. One-milliliter samples of the serial dilutions can be added to a tube of molten agar (48 °C) for the preparation of a pour plate.

Alternatively, 0.1-mL samples of the serial dilutions can be pipetted onto prewarmed (35 °C for 1 hour) agar plates and distributed evenly using sterile, bent glass rods. Yet another

method uses 20 to 50 mL samples which are dropped on each of five spots onto prewarmed agar plates and allowed to absorb without streaking.

Whichever method is used, the minimal, accurately detectable number of CFU/mL must be determined by serial dilutions with a known inoculum. Potential drug carryover (Section 6) must be evaluated and, if a problem, steps taken to eliminate these effects. Colonies are counted after 24 to 48 hours of incubation. A magnifying lens can facilitate colony counts when plates are incubated for 24 hours. Prolonged incubation (48 hours) facilitates counting colonies as the colonies are larger. With certain organism/ antibiotic combinations, the resultant colonies may be changed (i.e., dwarf size and not readily detected). Prolonged incubation of plates before colonies are counted may be more accurate. The kill-kinetic determinations are shown graphically by plotting \log_{10} CFU against time. A bactericidal effect can be seen by a $\geq 3 \log_{10}$ CFU decrease (99.9% killing of the final inoculum) at the time specified.

During the performance of these studies, colony counts may show a final increase in number after an initial decrease. This can be due to the selection of resistant isolates (most often phenotypic resistance⁶¹), inactivation of the antimicrobial agent (most likely after 24 hours), or regrowth of susceptible bacteria which have escaped the antimicrobial activity by adhering to the wall of the test tube.^{57,62,63} When regrowth occurs, it is useful to determine the MICs of survivors in order to see if a resistant organism was selected from the population tested.

For comparisons of serum bactericidal rates, linear regression analysis can be done¹² with the serum bactericidal rate being defined as the slope of the regression line, and its units being the change in the \log_{10} CFU per milliliter per hour of exposure to the agent. The more negative the slope, the faster the rate of bacterial killing. A positive slope (e.g., in controls) indicates growth. Alternatively, the area-under-the-killing-curve⁶⁴ can be determined. Unlike linear regression analysis, the latter method allows for nonlinear segments in the curves. The serum bactericidal rate has mainly been used as a research tool, but has potential usefulness in clinical situations.^{19,36}

6 Antibiotic Carryover

The transfer of a quantitated volume of broth from the serum inhibitory titers or from a kill-kinetic determination in order to assess the number of survivors can be complicated by antibiotic carryover.⁶⁵ This problem occurs mainly when higher concentrations of antibiotic are present and is especially common when testing β -lactam agents and staphylococci. Antibiotic carryover can be detected by streaking the sample subcultured across the surface of a prewarmed agar plate, allowing 20 minutes for antimicrobial absorption into the agar, then cross-streaking the test organism over the entire surface of the plate, and after 24 hours of incubation looking for inhibition of colonial growth at the site of the initial streak.⁶⁰ This effect can be minimized by allowing inoculum to dry on the agar surface before spreading.

7 Quality Control

7.1 Purpose

The quality control program monitors:

- The precision and accuracy of the susceptibility test procedure, including the inoculum size and the growth of the microorganism.
- The performance of reagents.
- The individuals who perform the test and read the results.

This goal is best realized through the use of reference strains selected for their genetic stability and for their usefulness in the particular method being controlled.

7.2 Selecting Reference Strains

Ideal reference strains for quality control of dilution susceptibility methods have MICs (and MBCs) that fall near the midrange of the concentration for all antimicrobials tested. An ideal control strain is inhibited at the fourth dilution of a seven dilution \log_2 series, but strains with MICs (and MBCs) at either the third or fifth dilution are acceptable. The reference strains will be used primarily as quality control measures for occasional testing of the media

used in bactericidal testing and for occasional testing of individuals who perform the test.

7.3 Suggested Quality Control Strains

A full set of quality control strains that have adequate or optimal endpoints for all the commonly used antimicrobial agents is not yet available. Some strains with useful endpoints, however, have been tested repeatedly and have proven to be stable. We currently recommend the following reference strains for controlling dilution tests:

- *Escherichia coli* ATCC® 25922
 - *Pseudomonas aeruginosa* ATCC® 27853
 - *Staphylococcus aureus* ATCC® 25923
 - *Enterococcus faecalis* ATCC® 29212.
- For suitable quality control ranges, see Table 3.

7.4 Batch or Lot Control

Records should be kept of the lot numbers of all materials and reagents used in these tests.

7.5 Other Control Procedures

7.5.1 Growth Control

Each macrodilution series and each microdilution tray should include a positive growth control of basal medium without antimicrobial agent to assess viability of the test organisms. The growth control also serves as a turbidity control for reading endpoints.

7.5.2 Purity Control

A sample of the inoculum should be streaked on a suitable agar plate and incubated overnight to detect mixed cultures and to provide freshly isolated colonies in case retesting proves necessary. Also, the growth control can be subcultured at the same time that the serum bactericidal test is performed in order to assess purity.

7.5.3 Reproducibility

If serum dilution titers are determined by the microdilution method, the reproducibility can easily be determined by performing the test in duplicate.

7.5.4 Paradoxical Effect

The paradoxical effect is defined as the occurrence of progressively increasing plate counts for at least three consecutive concentrations above the serum inhibitory titer. If this occurs, the concentrations exhibiting the paradoxical effect are usually ignored for *S. aureus* but are reported when dealing with

those gram-negative bacteria which can be inducible/constitutive producers of Class C (Group 1) β -lactamase (e.g., *Enterobacter*, *P. aeruginosa*). Paradoxical effect can also be seen with quinolones once the maximum bactericidal concentration has been exceeded.

Table 1. Rejection Value and Calculated Sensitivity and Specificity for Each Initial Concentration on the Basis of Duplicate 0.01-mL Samples^a

5% Error (Pipette error plus full sampling error) for Determination of Final Inoculum^b

Final Inoculum (CFU/mL)	Rejection Value ^c	Sensitivity ^d (%)	Specificity ^d (%)
1 x 10 ⁵	4	77	97
2 x 10 ⁵	8	89	99
3 x 10 ⁵	15	99	99
4 x 10 ⁵	20	99	99
5 x 10 ⁵	25	99	99
6 x 10 ⁵	29	99	99
7 x 10 ⁵	33	99	99
8 x 10 ⁵	38	99	99
9 x 10 ⁵	42	99	99
1 x 10 ⁶	47	99	99
2 x 10 ⁶	91	99	99
3 x 10 ⁶	136	99	99
4 x 10 ⁶	182	99	99
5 x 10 ⁶	227	99	99
6 x 10 ⁶	273	99	99
7 x 10 ⁶	318	99	99
8 x 10 ⁶	364	99	99
9 x 10 ⁶	409	99	99
1 x 10 ⁷	455	99	99

^aWhen the sum of colonies from duplicate samples was equal to or less than the rejection value, the antibiotic was declared lethal (a 0.999 or greater reduction in the final inoculum).

^bBased on duplicate samples for the determination of the final inoculum size.

^cNumber of colonies.

^dSensitivity and specificity calculated for each specific final inoculum concentration and rejection value.

Table 2. Rejection Value and Calculated Sensitivity and Specificity for Each Initial Concentration on the Basis of a Single 0.01-mL Sample^a

5% Error (Pipette error plus full sampling error) for Determination of Final Inoculum^b

Final Inoculum (CFU/mL)	Rejection Value ^c	Sensitivity ^d (%)	Specificity ^d (%)
1 x 10 ⁵	3	84	83
2 x 10 ⁵	4	87	97
3 x 10 ⁵	6	84	98
4 x 10 ⁵	8	89	99
5 x 10 ⁵	11	96	99
6 x 10 ⁵	15	99	99
7 x 10 ⁵	17	99	99
8 x 10 ⁵	20	99	99
9 x 10 ⁵	23	99	99
1 x 10 ⁶	25	99	99
2 x 10 ⁶	47	99	99
3 x 10 ⁶	68	99	99
4 x 10 ⁶	91	99	99
5 x 10 ⁶	113	99	99
6 x 10 ⁶	136	99	99
7 x 10 ⁶	159	99	99
8 x 10 ⁶	182	99	99
9 x 10 ⁶	204	99	99
1 x 10 ⁷	227	99	99

^aWhen the number of colonies from a single sample was equal to or less than the rejection value, the antibiotic was declared lethal (a 0.999 or greater reduction in the final inoculum).

^bBased on a single sample for the determination of the final inoculum size.

^cNumber of colonies.

^dSensitivity and specificity calculated for each specific final inoculum concentration and rejection value.

Table 3. Suitable Quality Control Ranges for MICs and MBCs With and Without Human Serum Using ATCC Strains^a

<i>Staphylococcus aureus</i> ATCC® 25923				
Drug	MIC in		MBC in	
	CAMHB ^b	CAMHB/HS ^c	CAMHB ^b	CAMHB/HS ^c
Methicillin	1-4	1-4	1-4	1-4
Oxacillin	0.125-0.5	0.5-2	0.25-1	1-4
Nafcillin	0.125-0.5	0.5-2	0.25-1	1-4
Cephalothin	0.0625-0.25	0.25-1	0.125-0.5	0.5-2
Cefazolin	0.125-0.5	0.5-2	0.125-0.5	1-4
Vancomycin	0.5-2	0.5-2	1-4	1-4
<i>Escherichia coli</i> ATCC® 25922				
Drug	MIC in		MBC in	
	CAMHB ^b	CAMHB/HS ^c	CAMHB ^b	CAMHB/HS ^c
Ampicillin	2-8	2-8	4-16	4-16
Piperacillin	1-4	1-4	2-8	2-8
Cephalothin	8-32	16-64	16-64	32-128
Imipenem	0.0625-0.25	0.25-1	0.125-0.5	0.25-1
Gentamicin	0.25-1	1-4	0.25-1	1-4
Amikacin	0.5-2	2-8	0.5-2	2-8
<i>Pseudomonas aeruginosa</i> ATCC® 27853				
Drug	MIC in		MBC in	
	CAMHB ^b	CAMHB/HS ^c	CAMHB ^b	CAMHB/HS ^c
Piperacillin	4-16	2-8	8-32	4-16
Ticarcillin	32-128	16-64	32-128	16-64
Imipenem	1-4	2-8	4-16	8-32
Gentamicin	2-8	2-8	4.0-16	4-16
Tobramycin	0.5-2	0.5-2	1-4	1-4
Amikacin	2-8	2-8	4-16	4-16

^aAlthough these quality control ranges are derived from a published study, it should be noted that this study was performed before NCCLS document M23—*Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters* defined the parameters for such studies.

^bCAMHB = cation-adjusted Mueller-Hinton broth.

^cCAMHB/HS = cation-adjusted Mueller-Hinton broth mixed with pooled human serum in a 1:1 ratio.

References

- ¹ NCCLS. *Performance Standards for Antimicrobial Disk Susceptibility Tests Sixth Edition; Approved Standard*. NCCLS document M2-A6. Wayne, Pennsylvania: NCCLS;1997.
- ² NCCLS. *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically Fourth Edition; Approved Standard*. NCCLS document M7-A4. Wayne, Pennsylvania: NCCLS; 1997.
- ³ NCCLS. *Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria Fourth Edition; Approved Standard*. NCCLS document M11-A4. Wayne, Pennsylvania: NCCLS;1997.
- ⁴ Isenberg HD. Clinical evaluation of laboratory guidance to antibiotic therapy. *Health Lab Science*. 1967;4:166-180.
- ⁵ Hunter TH. Speculations on the mechanism of cure of bacterial endocarditis. *J Am Med Assoc*. 1950;144:524-527.
- ⁶ Scheld WM, Sande MA. Bactericidal versus bacteriostatic antibiotic therapy of experimental pneumococcal meningitis in rabbits. *J Clin Invest*. 1983;71:411-419.
- ⁷ Weinstein MP, et al. Multicenter collaborative evaluation of a standardized serum bactericidal test as a predictor of therapeutic osteomyelitis. *Am J Med*. 1987;83:218-222.
- ⁸ Sculier JP, Klastersky J. Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. *Am J Med*. 1984;76:429-435.
- ⁹ NCCLS. *Methods for Determining Bactericidal Activity of Antimicrobial Agents; Tentative Guideline*. NCCLS document M26-A. Wayne, Pennsylvania: NCCLS; 1999.
- ¹⁰ Vogelmann B, Craig WA. Kinetics of antimicrobial activity. *J Pediatr*. 1986; 108:835-840.
- ¹¹ Barriere SL, et al. Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal titer curve. *J Antimicrob Chemother*. 1985;16:49-59.
- ¹² Briceland LL, Pasko MT, Mylotte JM. Serum bactericidal rate as a measure of antibiotic interactions. *Antimicrob Agents Chemother*. 1987;31:679-685.
- ¹³ Wolfson JS, Swartz MN. Serum bactericidal activity as a monitor of antibiotic therapy. *N Engl J Med*. 1985;213:968-975.
- ¹⁴ Stratton CW. The serum bactericidal test. *Clin Microbiol Rev*. 1988;1:19-26.
- ¹⁵ Coleman DL, Horwitz RI, Andriole VT. Association between serum inhibitory and bactericidal concentrations and therapeutic outcome in bacterial endocarditis. *Am J Med*. 1982; 73:260-267.
- ¹⁶ Weinstein MP, et al. Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis. *Am J Med*. 1985;78:262-269.
- ¹⁷ Parker RH, Fossieck BE Jr. Intravenous followed by oral antimicrobial therapy for staphylococcal endocarditis. *Ann Intern Med*. 1980;93:832-834.
- ¹⁸ Sande MA, Sheld WM. Combination therapy of bacterial endocarditis. *Ann Intern Med*. 1980;92:390-395.
- ¹⁹ Drake TA, Hackbarth CJ, Sande MA. Value of serum tests in combined drug therapy of endocarditis. *Antimicrob Agents Chemother*. 1983;24:653-657.
- ²⁰ Klastersky J, Daneau D, Swings G, Weerts D. Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. *J Infect Dis*. 1974;129:187-193.
- ²¹ Drusano G, et al. Correlation of predicted serum bactericidal activities and values measured in volunteers. *Eur J Clin Microbiol*. 1986;5:88-92.

- 22 Dich VQ, Nelson JD, Hatalin KC. Osteomyelitis in infants and children. *Am J Dis Child*. 1975;129:1273-1278.
- 23 Tetzlaff TR, McCracken GH. Oral antibiotic therapy for skeletal infections in children. II. Therapy of osteomyelitis and suppurative arthritis. *J Pediatr*. 1978; 92:485-490.
- 24 Kolyvas E, et al. Oral antibiotic therapy of skeletal infections in children. *Pediatrics*. 1980;65:867-871.
- 25 Prober CG, Yeager AS. Use of the serum bactericidal titer to assess the adequacy of oral antibiotic therapy in the treatment of acute hematogenous osteomyelitis. *J Pediatr*. 1979;95:131-135.
- 26 Syrogiannopoulos GA, Nelson JD. Duration of antimicrobial therapy for acute suppurative osteoarticular infections. *Lancet*. 1988;1:37-40.
- 27 Black J, Hunt TL, Godley PJ, et al. Oral antimicrobial therapy for adults with osteomyelitis or septic arthritis. *J Infect Dis*. 1987;155:963-972.
- 28 Norden C, Gillespie WJ, Nade S. *Infections in Bones and Joints*. Blackwell Scientific Publications; 1994.
- 29 Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of peak concentration to minimal inhibitory concentration. *J Infect Dis*. 1987;155:93-99.
- 30 Stratton CW, Weinstein MP, Reller LB. Correlation of serum bactericidal activity with antimicrobial agent level and minimal bactericidal concentration. *J Infect Dis*. 1982; 145:160-168.
- 31 Peloquin CA, et al. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. *Arch Intern Med*. 1989;149: 2269-2273.
- 32 Moore RD, Smith CR, Lietman PD. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. *Am J Med*. 1984; 77:657-662.
- 33 Warren JW, Miller Jr EH, Fitzpatrick B, DiFranco DE, Caplan ES, Tenney JH, Anthony WC. A randomized, controlled trial of cefoperazone vs cefamandole-tobramycin in the treatment of putative, severe infections with gram-negative bacilli. *Rev Infect Dis*. 1983;5:173.
- 34 Barriere SL, Ozasa DC, Mordenti J. Assessment of serum bactericidal activity after administration of cefoperazone, cefotaxime, ceftizoxime and moxalactam to healthy subjects. *Antimicrob Agents Chemother*. 1985;28:55-57.
- 35 Goodpasture HC, et al. Optimal cefotaxime dosing for gram-negative bacteremia: effective trough serum bactericidal titers and drug concentrations 8 and 12 hr after 1- or 2-g infusions. *Diagn Microbiol Infect Dis*. 1988;9:97-103.
- 36 Drake TA, Sande MA. Studies of the chemotherapy of endocarditis: correlation of *in vitro*, animal model, and clinical studies. *Rev Infect Dis*. 1983;5(Suppl 2):S345-S354.
- 37 Zak D, Sande MA. In: Sabath LD, ed. Correlation of *in vitro* antimicrobial activity of antibiotics with results of treatment in experimental animal models and human infection. *Action of Antibiotics in Patients*. Bern, Switzerland: Han Huber Publishers; 1982:55-67.
- 38 Van der Auwera P, Van Laethem Y, Klastersky J. Bactericidal activity and killing rate of serum against gram-positive cocci in volunteers receiving imipenem, oxacillin, vancomycin, or ampicillin plus gentamicin. *J Antimicrob Chemother*. 1987;20:239-249.
- 39 Fan W, et al. Imipenem-cilastin in the treatment of methicillin-sensitive and methicillin-resistant *Staphylococcus aureus* infections. *Antimicrob Agents Chemother*. 1986;29:26-29.

-
- 40 Greenwood D. *In vitro* veritas? Antimicrobial susceptibility tests and their clinical relevance. *J Infect Dis.* 1981; 144:380-385.
- 41 Pien FD, Vosti KL. Variation in performance of the serum bactericidal test. *Antimicrob Agents Chemother.* 1974; 6:330-333.
- 42 Stratton CW, Reller LB. Serum dilution test for bactericidal activity. I. Selection of a physiologic diluent. *J Infect Dis.* 1977;136:187-195.
- 43 Kunin CM. Protein binding of antibiotics does affect their antistaphylococcal activity. *J Antimicrob Chemother.* 1986; 17:263.
- 44 Bergan T, Engeset A, Olszewski W. Does serum protein binding inhibit tissue penetration of antibiotics? *Rev Infect Dis.* 1987;9:713-718.
- 45 Rolinson GN. The significance of protein binding of antibiotics in antibiotic activity *in vivo*. *J Antimicrob Chemother.* 1980; 6:311-317.
- 46 Chambers HF, et al. Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to *Staphylococcus aureus*. *Rev Infect Dis.* 1984;6(Suppl 4):S870-S874.
- 47 Calain P, et al. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. *J Infect Dis.* 1987;155:187-191.
- 48 Bolivar R, Fainstein D, Elting K, Bodey GP. Cefoperazone for treatment of infections in patients with cancer. *Rev Infect Dis.* 1983;5(Suppl 1):181-187.
- 49 Peterson LR, et al. Influence of protein binding on therapeutic efficacy of cefoperazone. *Antimicrob Agents Chemother.* 1989;33:566-568.
- 50 Leggett JE, Wolz SA, Craig WA. Use of serum ultrafiltrate in the serum bactericidal test. *J Infect Dis.* 1989;160:616-623.
- 51 Reimer LG, Stratton CW, Reller LB. Minimal inhibitory and bactericidal concentrations of 44 antimicrobial agents against three standard control strains in broth with and without human serum. *Antimicrob Agents Chemother.* 1981;19:1050-1055.
- 52 Anhalt JP, Nelson R. Failure of PADAC test strips to detect staphylococcal β -lactamase. *Antimicrob Agents Chemother.* 1982;21:993-999.
- 53 Woolfrey BF, Lally RT, Tait KR. Influence on technical factor variations on serum inhibitions and bactericidal titers. *J Clin Microbiol.* 1986;23:997-1000.
- 54 Pearson RD, Steigbigel RT, Davis HT, Chapman SW. Method for reliable determination of minimal lethal antibiotic concentrations. *Antimicrob Agents Chemother.* 1980;18:699-708.
- 55 Shanholtzer CJ, Peterson LR, Mohn ML. MBCs for *Staphylococcus aureus* as determined by macrodilution and microdilution techniques. *Antimicrob Agents Chemother.* 1984;26:214-219.
- 56 Sherris JC. Problems *in vitro* determination of antibiotic tolerance in clinical isolates. *Antimicrob Agents Chemother.* 1986;30:633-637.
- 57 Taylor PC, et al. Determination of minimum bactericidal concentrations of oxacillin for *Staphylococcus aureus*: influence and significance of technical factors. *Antimicrob Agents Chemother.* 1983;23:142-150.
- 58 Miles AA, Misra SS. The estimation of the bactericidal power of the blood. *J Hyg (Lond).* 1938;38:732-748.
- 59 Peletier LL. Lack of reproducibility of macrodilution MBCs for *Staphylococcus aureus*. *Antimicrob Agents Chemother.* 1984;26:815-818.

-
- ⁶⁰ Pelletier Jr LL, Baker CB. Oxacillin, cephalothin, and vancomycin tube macrodilution MBC result reproducibility and equivalence to MIC results for methicillin-susceptible and reputedly tolerant *Staphylococcus aureus* isolates. *Antimicrob Agents Chemother.* 1988; 32:374-377.
- ⁶¹ Greenwood D. Phenotypic resistance to antimicrobial agents. *J Antimicrob Chemother.* 1985;15:653-658.
- ⁶² Gwynn MN, Webb LT, Rolinson GN. Regrowth of *Pseudomonas aeruginosa* and other bacteria after the bactericidal action of carbenicillin and other beta-lactam antibiotics. *J Infect Dis.* 1981;144:263-269.
- ⁶³ Layte S, Harris P, Rolinson GN. Factors affecting the apparent regrowth of *Pseudomonas aeruginosa* following exposure to bactericidal concentrations of carbenicillin. *Chemotherapy.* 1983;30:26-30.
- ⁶⁴ Tisdale JE, Pasko MT, Mylotte JM. Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curve. *Antimicrob Agents Chemother.* 1989; 33:1500-1505.
- ⁶⁵ Dankert J, Holloway Y, Joldersma W, Hess J. Importance of minimizing carry-over effect at subculture in the detection of penicillin-tolerant viridans group streptococci. *Antimicrob Agents Chemother.* 1983;23:614-616.

Additional References

Craig WA, Gudmundsson S. Postantibiotic effect. In: *Antibiotics in Laboratory Medicine*. 4th ed. Williams and Wilkins Co.;1996:2.

Odenholt-Tornqvist I, Lowdin E, Cars O. Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin. *Antimicrob. Ag Chemother.* 1992;36:1852-1858.

Summary of Comments and Subcommittee Responses

M21-T: *Methodology for the Serum Bactericidal Test; Tentative Guideline*

General Comments

1. I would argue that a critical review of the clinical relevance of the serum bactericidal test to the clinical setting be a part of the document.
- **Serum bactericidal tests by different methods have been used for 50 years; however, critical assessments of clinical utility are few and not sufficient. A principal goal of an approved NCCLS serum bactericidal testing guideline is to foster the very studies that could become references in future documents.**
2. While I have many concerns about the use of this test in most clinical laboratories, I believe it is possible to obtain reproducible answers depending on the technology that is employed in performing the test.
- **Ensuring reproducibility of results with this testing methodology is the main objective of this serum bactericidal testing guideline.**
3. We avoid the use of serum additive because it introduces a major, uncontrolled variable to the test, and the direct effects of serum on antimicrobial agent performance due to protein binding during patient treatment can be estimated easily. Because of the poor reproducibility of the MBC test, it should always be run in duplicate. When the macrodilution method is used, the subculture should be repeated after 48 hours of incubation if the results at 24 hours show skips or are discrepant. Also, we do not recommend any agitation before sampling.
- **Using the microdilution methodology in this document should enable a reproducible result. An ultrafiltrate of the patient's serum is an acceptable alternative to dilution with pooled human serum as noted.**
4. Since this test has quite limited scientific evidence correlating a single or specific titer to therapeutic outcome, I would strongly encourage NCCLS in the next revision of this document to not publish specific interpretive criteria.
- **This comment is duly noted. The importance of keeping abreast of the medical literature on this topic has been emphasized in this version.**
5. Many viridans streptococci are capable of growing in broth with chain lengths exceeding 100 cells. These chains are not easily disrupted; placing the culture (in a glass container) in an ultrasonic waterbath has little effect on chain length. I believe that this is a major technical factor in the irreproducibility of time-kill and associate methodology, particularly for viridans streptococci. The time period for which the organism is grown in broth prior to standardization of the inoculum using a McFarland standard will affect the initial chain length obtained (factors such as the length of the lab phase resulting in a change of media formulation from agar-plate to broth, the degree of metabolic shutdown relating the age of the culture on the plate which the broth was inoculated and the time taken to reach opacity all affect the chain length of organisms in broth). Sonication of the sample used to assess the initial inoculum in such tests does go some way to addressing this technical factor, and if properly controlled should result in more reproducible methods.
- **The relevance of this comment has been noted.**

Foreword

6. Last sentence - Should this read "The assistance of the laboratory's director is useful in (1) determining if such a test is needed, (2) selecting NCCLS recommended methodology for testing and (3) interpreting the results"?

- **The wording in the Foreword has been revised accordingly.**

Section 1.1

7. Is "integrates" the appropriate word, or would something like "incorporate" be more accurate? The word "integrate" is used repeatedly throughout the document in this same sense.

- **The indicated wording has been revised accordingly.**

8. The serum bactericidal test which can determine the magnitude of bacterial activity. . .The word "magnitude" does not read well and is repeated.

- **This comment has been noted and the text revised.**

Section 2.2

9. Add a sentence for those physicians submitting to referral laboratories. We suggest. . ."If submitted frozen to a referral laboratory for testing, submit in a sterile plastic vial. Do not use glass."

- **This comment has been noted and the text revised.**

Section 3.1

10. The sentence "The greatest effect. . ." is awkward; suggest rewording.

- **This comment has been noted and the text revised.**

11. Could a list of such agents affected by protein binding be provided (recognizing that new agents are always being released)?

- **This comment has been noted and the text revised.**

Section 3.1.2

12. With the emphasis on use of the ultrafiltrate, could these details be deleted or relegated to an appendix?

- **Details on the use of the ultrafiltrate should be in the text itself for laboratories that use pooled human serum.**

Section 3.3

13. It is not necessary to prepare the inoculum by using 20 to 30 colonies. We suggest that 5 to 10 colonies would work as well.

- **This comment has been noted and the text revised.**
- 14. It is suggested, when attempting to count viable colonies from the growth control well inoculum and using a micropipettor to drop dilutions, that this be done in duplicate and the numbers of colonies be counted and averaged to give a better representation of initial inoculum size.

- **This comment has been noted and the text revised.**

Section 3.5

15. Specify atmospheric conditions of incubation, i.e., ambient, CO₂, or other.

- **The atmospheric conditions have been added to the text.**

Section 3.6

16. The term "rejection values" is not clear. Define the term and how it should be used.

- **A working definition of this term has been incorporated into the text of Section 3.6.**

Section 6.0

17. There are no instructions for preparing a diluted sample.

- **Detailed instructions regarding diluted sample preparation have been added to Section 6.**

Related NCCLS Publications*

- M2-A6** **Performance Standards for Antimicrobial Disk Susceptibility Test Sixth Edition; Approved Standard (1997).** This document provides current recommended techniques for disk susceptibility testing, new frequency criteria for quality control testing, and updated tables for interpretive zone diameters.
- M7-A4** **Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically Fourth Edition; Approved Standard (1997).** This document provides reference methods for the determination of minimum inhibitory concentrations (MIC) of aerobic bacteria by broth macrodilution, broth microdilution, and agar dilution.
- M11-A4** **Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard Fourth Edition (1997).** This document provides methods for susceptibility testing of anaerobic bacteria; description of reference agar dilution method, alternative agar methods (Wadsworth and limited dilutions), broth microdilution, and broth (macro) dilution procedures, and quality control criteria for each procedure.
- M26-A** **Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline (1999).** This document provides procedures for determining the lethal activity of antimicrobial agents.
- M29-A** **Protection of Laboratory Workers from Instrument Biohazards and Infectious Disease Transmitted by Blood, Body Fluids, and Tissue; Approved Guideline (1997).** This document provides guidance on the risk of transmission of hepatitis viruses and human immunodeficiency viruses in any laboratory setting; specific precautions for preventing the laboratory transmission of blood-borne infection from laboratory instruments and materials; and recommendations for the management of blood-borne exposure.

* Proposed- and tentative-level documents are being advanced through the NCCLS consensus process; therefore, readers should refer to the most recent editions.

NOTES

NOTES

NOTES

NOTES

NOTES

NOTES

NOTES

NCCLS ▼ 940 West Valley Road ▼ Suite 1400 ▼ Wayne, PA 19087 ▼ USA ▼ PHONE 610.688.0100

FAX 610.688.0700 ▼ E-Mail: exoffice@nccls.org.

ISBN 1-56238-383-3

